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Abstract
Kinstedt, Christine Morgan. M.S., Department of Neuroscience, Cell Biology, and
Physiology, Wright State University, 2021. Using Functionalized Benzylidene Oxindoles
to Determine an Improved Monoamine Oxidase-B Inhibitor as a Therapeutic Agent for
Parkinson’s Disease.

With the intent to create an optimized monoamine oxidase-B (MAO-B) inhibitor,
researchers in this investigation synthesized derivatives of the benzylidene oxindole
scaffold in order to determine a lead molecule for further drug development. Previous
work in this laboratory group evaluated a similar scaffold, the chalcone structural unit. As
this class of compounds was determined to possess the ability to permeate the blood brain
barrier (BBB) and to act as potent MAO-B inhibitors, it was posited that scaffold hopping
from this previously studied molecular skeleton to benzylidene oxindoles would provide
analogous results. Benzylidene oxindoles are readily synthesized via the Claisen-Schmidt
condensation of an indolin-2-one and a substituted benzaldehyde. Based on this simple
synthesis, a large library of compounds has the potential to be made readily, increasing
the possibility that a lead molecule may be determined subsequent to biological
screening. During the course of this research investigation, a large, although not
exhaustive, number of functionalized benzylidene oxindoles was synthesized in order to
determine which structural units would improve the scaffold’s ability to act as a
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reversible MAO-B specific inhibitor. This could then potentially be used in association
with the pro-drug Levadopa in order to ameliorate Parkinson’s disease symptoms.
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1. Introduction
1.1. Parkinson’s Disease
Parkinson’s disease (PD), first medically described by James Parkinson in 1817, 1
is the second most prevalent neurodegenerative disorder after Alzheimer’s disease.2 This
illness poses an immediate problem as an approximate sixty thousand Americans are
diagnosed each year3 with an estimated ten million diagnoses globally. 2 In the United
States alone, approximately fifty-two billion dollars per year is attributed to the cost of
PD.3 As the exact cause of the progression of PD is unknown, there is currently no cure 4-5
or foolproof method for diagnosing the disorder.6 Thus, the discovery of improved
treatments and therapeutic techniques is crucial to alleviate symptoms of the disease.
The progression of PD is characterized by a loss of coordination and muscle
movement as opposed to a loss of cognitive function as in AD. 7-8 This decline in physical
ability was originally described as a series of five stages in 1967 by Hoehn and Yahr.9 In
their description, a patient maintains total independence in the first three phases and
experiences only mild to moderate symptoms; however, once the patient enters stage
four, he or she has fully developed the disorder and is incapable of living without
assistance.9
Stage 1 of Parkinson’s disease is characterized by minimal symptoms (including
issues with posture, facial expressions, and movement) that are unilateral and affect
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solely one side of the body.4 An individual is described as entering stage 2 when the
symptoms worsen and become bilateral.4 In stage 3, individuals characteristically
experience similar symptoms as in stage 2, but decreased reflexes and a loss of balance
are also noted.4
Individuals in stages 4 and 5 of PD are generally incapable of safely maintaining
independence.4 During stage 4, patients are capable of standing without help, but
generally they require assistance for movements.4 Individuals in the final stage require
wheelchairs for movement and twenty-four-hour assistance in order to decrease the risk
of falls.4 Additionally, patients characterized as experiencing stage 4 and 5 symptoms
generally also possess a decline in mental faculties.4 Some individuals exhibit dementia,
hallucinations, and/or confusion.4

1.2. Basal Ganglia Circuitry and Pathways
An important neurobiological topic to discuss in regards to Parkinson’s disease is
its effect on the circuitry of the basal ganglia and the role of dopamine in its overall
functioning. The basal ganglia has a specific disinhibitory circuit based on levels of
GABA, dopamine, and glutamate present in the cholinergic neurons as shown in Figure
1.10 (Disinhibitory simply means that an inhibitory neuron is inhibited and, therefore, the
next step in the sequence can occur uninhibited.10) The majority of neurons in the basal
ganglia are GABAergic, or inhibitory, but some are glutamergic, or excitatory.10 The type
of signal (excitatory or inhibitory) passed from one anatomical structure to the next
ultimately has a large effect on the frontal cortex (FC) which is responsible for the
control of voluntary movement.10
2

Figure 1: Basal Ganglia Circuitry10
One of two pathways in the basal ganglia may be stimulated. The first is the direct
pathway shown in Figure 2.10 In this pathway, dopamine released from the substantia
nigra pars compacta (SNc) stimulates the striatum via D1 dopamine receptors, exciting
the inhibitory striatal medium spiny neurons at the caudate and putamen. 10 (These are the
major nuclei of the striatum.10) These neurons are excited and then release GABA, the
inhibitory neurotransmitter, onto the globus pallidus internus (GPi) and the substantia
nigra pars reticulata (SNpr).10 As the GPi and the SNpr possess inhibitory GABAergic
neurons, the inhibition of these neurons causes them to be incapable of firing their GABA
neurotransmitters onto the thalamus.10 The thalamus is therefore disinhibited and sends
glutamate, the excitatory neurotransmitter, to the FC.10 Glutamate then stimulates the FC,
allowing for initiation of movement.10

3

Figure 2: Direct Pathway of the Basal Ganglia10

The second pathway of the basal ganglia is the indirect pathway illustrated in
Figure 3. In this pathway, the SNc releases dopamine onto D2 dopamine receptors and
inhibits them.10 This causes the striatal neurons to be less excited, resulting in less
inhibitory GABA neurotransmitter sent to the GPe.10 As the GPe is no longer inhibited,
these neurons are excited and GABA is sent to the subthalamic nucleus.10 This results in
less glutamate sent to the GPi and SNpr, yielding a lack of excitation in these brain
regions.10 As the GPi and SNpr are no longer excited, a decreased level of GABA is sent
to the thalamus and results in excitation of these neurons.10 The thalamic neurons then
release more glutamate onto the FC, causing an excitation of these neurons and the
initiation of movement.10 Overall, both the direct and indirect pathways result in an
excitation of neurons present in the frontal cortex due to the release of dopamine.10

4

Figure 3: Indirect Pathway of the Basal Ganglia10

In PD, the levels of dopamine from the SNpc are greatly reduced, decreasing their
effects on both the D1 and D2 receptors of striatal neurons.10 This indicates that the
excitatory glutamatergic neurons from the cerebral cortex will then increase the activity
of D2R receptors and predominantly stimulate the indirect pathway as seen in Figure 4.10
As glutamate excites the striatum, it will then release GABA onto the GPe and
subsequently decrease its activity.10 This then disinhibits the subthalamic nucleus and
increases its release of glutamate onto the GPi/SNpr. 10 This excitation of the GPi/SNpr
causes a release of GABA, decreasing the activity of the thalamus.10 As the thalamus is
inhibited, less glutamate is released onto the FC and its activity is decreased. 10 This
results in the inability to create movements, a characteristic sign of PD. 9
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Figure 4: The Effect of Parkinson’s Disease on the Basal Ganglia10

1.3. Levadopa (L-dopa)
As stated previously, no true cure exists for PD;5 however, it has been realized
that a decrease in dopamine (1) in the basal ganglia has been correlated with the
symptoms of the illness.10-11 Dopaminergic neurons are deteriorated during PD, causing
the levels of dopamine to be lower than in healthy individuals. 5 In order to increase the
quality of life of those afflicted, the main focus of PD therapeutic agents relates to
augmenting the levels of this neurotransmitter in the brain.12 Unfortunately, dopamine is
a water-soluble compound11 incapable of permeating the blood-brain barrier (BBB) due
to its undesirable lipophilicity value (log P) of approximately 0.918 as calculated by
ChemDoodle.13 (Log P is the 1-octanol/water partitioning coefficient and it provides a
measurement of the hydrophobic character of a molecule.14) A compound must possess a
log P of approximately 1-3 in order to permeate the BBB.15 (Many central nervous
system (CNS) agents possess log P values around 2.15) To solve this problem, a molecule
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with analogous properties to dopamine, but with a desirable log P, would either need to
be synthesized and used in the place of this neurotransmitter, or a molecule that could be
enzymatically broken down into dopamine in vivo would need to be created.

The answer came as a therapeutic treatment known as levodopa (L-dopa) (2).11,16
This molecule was utilized as a pro-drug in order to be metabolized in vivo into
dopamine.17 (A pro-drug is a drug precursor that must undergo a chemical reaction in
order to become the pharmaceutical agent of interest. 18) L-dopa is a naturally occurring
molecule that was first isolated in 1913 by Marcus Guggenheim,16,19 but it was not used
as a PD therapeutic agent until 1967 when Cotzias et al. documented the sustained
improvement seen in a severely disabled PD patient.16,20 Due to its ability to ameliorate
PD symptoms and permeate the BBB using transport molecules,5 L-dopa remains the
standard treatment, in association with carbidopa (3),17 for this disease even fifty years
later.12,16-17 As L-dopa is naturally occurring and is the direct precursor to dopamine in
vivo,11 it would also make sense that L-dopa would be safe for human consumption.

Carbidopa is a decarboxylase inhibitor (DCI) which prevents L-dopa’s
metabolism by aromatic L-amino acid decarboxylase (AADC) into dopamine outside of
the BBB.17,21 The administration of these specific DCIs allows for lower dosages of the
7

pro-drug to be prescribed as an approximate 4-fold increase in L-dopa levels that are able
to enter the BBB before being metabolized has been reported.17,22 Therefore, carbidopa
inhibits peripheral metabolism of L-dopa to dopamine and allows for a higher
concentration of L-dopa to permeate the BBB, increasing dopamine in the basal
ganglia.22

L-dopa (2) is structurally similar to dopamine (1) and virtually chemically
analogous to L-tyrosine (4).17 Compounds 1, 2, and 3 are a class of molecules known as
catecholamines23 as they both possess the basic catechol structure24 (a 1,2dihydroxybenzene/benzene-1,2-diol substituent) (5) with primary amine moieties.
Compounds 1 and 2 differ greatly as 1 does not possess a chiral center and a carboxylic
acid functional group while L-dopa does. The same functional groups (phenol, carboxylic
acid, and primary amine) and chiral centers are present on molecules 2 and 4, yielding
analogous chemical activities for the two compounds. The only difference between these
is an extra hydroxyl group on the 3-position of the aromatic benzene ring for compound
2.

1.4. Nobel Prize Synthesis of L-dopa
In 2001, William Knowles won the Nobel Prize in Chemistry for asymmetric
hydrogenation.25-26 His work, utilizing the DiPAMP catalyst,27 afforded an
enantiomerically specific synthesis of L-dopa via the Erlenmeyer-Plöchl Azlactone
8

Synthesis provided in Scheme 1.17,28 Previously, both the L and D enantiomeric versions
were observed during synthesis. As enantiomers are difficult to separate due to their
identical physical properties,29 and as only the L version can be metabolized in vivo in
eukaryotes,30-31 Knowles alleviated some of the hassle of the synthesis of L-dopa.17 (This
also, therefore, increased its ability to be used as a pharmaceutical agent.)

Scheme 1: Erlenmeyer-Plöchl Azlactone Synthesis of L-dopa17,28
The first step in this synthesis involved an aldol type condensation reaction of 4hydroxy-3-methoxybenzaldehyde (6) with N-acetylglycine (7) followed by dehydrative
cyclization using acetic anhydride and sodium acetate led to the production of 2-methyl4-(3’-methoxy-4’-acetoxybenzal)-5-oxazolone (8).28 The azalactone derivative (8) was
then hydrolyzed using heat, water, and acetone in order to form -acetamido-4-hydroxy3-methoxy-cinnamic acid acetate (9).28 A selective reduction was then performed using
the DiPAMP catalyst resulting in the prochiral enamide molecule, N-acetyl-3-(4hydroxy-3-methoxyphenyl)alanine acetate (10).28 Aqueous hydrolysis was then
performed to yield the enantiomerically pure L-dopa molecule.28

9

1.5. Metabolic Breakdown of L-dopa
The biochemical pathway for the synthesis and breakdown of L-dopa, provided in
Scheme 2,17 presents vital information regarding enzymes that would act as suitable
therapeutic PD targets. The synthesis of L-dopa occurs in vivo, specifically in skin and
pigmented tissues, via the metabolism of L-tyrosine by tyrosine hydroxylase.22 The
resulting L-dopa molecule can be metabolized by either catechol-O-methyl transferase
(COMT) in the neuron to become 3-O-methyldopa (11) with the loss of an alcohol group
or by aromatic L-amino acid decarboxylase (AADC) to form dopamine with the loss of
the carboxylic acid moiety.11,17

Scheme 2: Metabolic Breakdown of L-dopa in Vivo17,22
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Upon formation of dopamine, synaptic vessels carry the neurotransmitter outside
of the neuron and it diffuses across the synaptic cleft to bind to the postsynaptic
membrane.32 Subsequent to binding to postsynaptic receptors, signal transduction
occurs.32 Following, the neurotransmitter is released from the receptor and undergoes
reuptake through a dopamine transporter back into the presynaptic neuron where it is
either broken down by monoamine oxidase-B or reenters the synaptic vesicles for later
use.32 (This entire process is depicted in Figure 5.33) If dopamine is further degraded by
monoamine oxidase, then the compound is oxidized into 3,4-dihydroxyphenyl acetic acid
(DOPAC) (12) with the conversion of a primary amine group into a carboxylic acid
structural moiety.17 DOPAC is then degraded by COMT to form homovanillic acid
(HVA) (13).17

Figure 5: The Pathway of Dopamine at the Synaptic Cleft 33
It is evident based upon Scheme 2 that several enzymatic inhibitors could be
synthesized in order to increase the levels of dopamine in the brain. As described
previously, L-dopa has the potential to originally be metabolized into 3-O-methyldopa.17
11

This compound is not recognized by AADC and is therefore unable to be broken down
into the desired dopamine neurotransmitter.17 Thus, by synthesizing a COMT inhibitor,
the relative amounts of L-dopa present in the brain would increase and more would be
converted into dopamine as described previously. Another suitable target for increasing
dopamine levels is monoamine oxidase-B.17 If the action of this enzyme was reduced,
then dopamine would be broken down less in the presynaptic cell and more would be
stored in the synaptic vessels until needed for further use. 33
Both of these enzymes independently provide suitable targets for future
development of PD therapeutic agents. The best treatment for the symptoms of PD,
however, would include three medications that, when used simultaneously, could
decrease the enzymatic activity of COMT, MAO-B, and AADC peripherally to yield
maximum conversion to dopamine in the brain and less degradation to DOPAC or 3-Omethyldopa. The main target of this investigation was the monoamine oxidase-B enzyme
and the development of inhibitors for this protein will be described herein.

1.6. Monoamine Oxidase (MAO) Enzyme
The monoamine oxidase enzyme (MAO) exists in two separate isoforms17,34-35 in
mammals,36 monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B).
These are derived from different genes.35 Both MAO isozymes are found in neurons, glial
cells,37 and astrocytes in the central nervous system (CNS); 38 however, MAO-A is the
isoform primarily expressed in the GI tract and the liver. 38 Despite this prevalence of
MAO-A outside of the CNS, 20 % and 50 % of total activity in the gut wall and liver
respectively are associated with MAO-B.39 In the brain, MAO-B is located in
12

serotonergic37,40-41 and histaminergic40 neurons with the highest concentration in the
raphe nuclei;41 whereas, MAO-A is present in catecholaminergic (including serotinergic
and noradrenergic) neurons and the highest concentration is localized in the locus
coerulus.41 Both the locus coerulus and the raphe nuclei are located in the brainstem: the
locus coerulus resides in the pons42 and the raphe nuclei are present near the midbrain.43
(The brainstem, which connects the cerebrum and the spinal cord, is comprised of the
midbrain, pons, and the medulla oblongata.44)

Both of these outer mitochondrial membrane proteins45 are responsible for
oxidative deamination of specific monoamine neurotransmitters.34 MAO-A metabolizes
serotonin (14), norepinephrine (15), epinephrine (16), tyramine (17), and dopamine;46
whereas, MAO-B is primarily responsible for the degradation of dopamine17 and also
partially for tyramine.47 Serotonin is a hormone present in the body that has a large
impact on mental health as it influences mood, happiness, and anxiety.48 Lower levels
have also been associated with depression, but the correlation between serotonin and
depression has not been validated.48
Norepinephrine and epinephrine are hormones secreted by the sympathetic
nervous system.49 Both augment blood glucose levels.49-50 Additionally, norepinephrine
elevates blood pressure and free fatty acid circulation,50 while epinephrine increases
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cardiac output.49 Tyramine elevates blood pressure51 and is readily metabolized by MAO,
yielding low levels of this compound in vivo under normal conditions.52
Inhibitors of MAO-A and MAO-B are utilized for different purposes. As MAO-A
lowers serotonin levels,46 inhibitors of this isozyme have the potential to act as
antidepressants. Molecules with the ability to reduce the activity of MAO-B are used as
PD drugs as they boost dopamine levels.17 MAO-B specific inhibitors, as compared to
MAO-A inhibitors, result in greater increases in dopamine as MAO-B targets this
neurotransmitter principally; whereas, MAO-A also oxidizes other important
monoamines as stated previously.17,46
Nonspecific inhibitors would cause elevated levels of all the aforementioned
monoamine neurotransmitters in variable amounts. Subsequently, schizophrenic
delusions and hallucinations, insomnia, disorientation, hypotension53 and hypertensive
crisis54 have all been reported.55 (Several nonspecific inhibitors include tranylcypromine
and phenelzine.53-55) As the two separate isoforms of the enzyme function in vastly
different ways, it is critical to create an inhibitor that specifically targets one isoform or
the other in order to avoid deleterious side effects.
In addition to enzyme specificity for MAO-A or MAO-B, the reversibility of
these synthesized inhibitors is also critically important. An irreversible enzyme
permanently halts enzymatic function generally via the formation of a covalent bond;57
therefore, the enzymatic pathway will remain inactive until more of the enzyme is
produced by the body. As MAO-B also functions in the gut and liver, though to a smaller
extent than MAO-A,39 irreversible inhibition of this enzyme could cause significant side
effects in other areas as these biochemical pathways would no longer work. The turnover
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number indicates the maximum number of substrate molecules converted to products per
active site on an enzyme per unit time.58 As MAO-B turnover in baboons shows a halflife of recovery of thirty days59 and 94 % of DNA is conserved between humans and
baboons,60 an irreversible inhibitor could potentially cease all MAO-B activity for
approximately a month. This could cause a significant amount of damage to the body.
These issues can include cardiovascular toxic effects and the development of
schizophrenia. As MAO-B is concurrently responsible for the breakdown of tyramine and
dopamine,38 inhibition of this isozyme may result in an increase of tyramine in the body.
Tyramine uptake into neurons causes the release of catecholamines including
norepinephrine.61 Elevated levels of this trace amine can ultimately yield hypertensive
crisis.61 Hypertensive crisis is a dangerously severe elevation in blood pressure at or
above 180 mmHg for systolic pressure and 120 mmHg for diastolic pressure.62
Individuals prescribed with monoamine oxidase inhibitors (MAOIs), especially
irreversible inhibitors, must alter their diet to limit tyramine-rich foods in order to avoid
these potentially life-threatening complications.63 As psychotic disorders including
schizophrenia have been associated with increased dopamine levels, 64 an irreversible
inhibitor has the capability to also cause psychosis.65

Despite the issues associated with selective irreversible inhibitors for MAO-B,
several molecules in this class of compounds have been approved by the FDA. The three
molecules are pargyline (18),66 selegiline (19),17 and rasagiline (20).17 Pargyline was first
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marketed in 1963 under the brand name Eutonyl as an antihypertensive agent66 that
functioned as a monoamine oxidase inhibitor (MAOI).67 The drug was later
discontinued,66,68 presumably related to the many adverse interactions between MAOIs
and over-the-counter (OTC) medications.69 Selegiline, commonly known as Zelapar, was
first FDA-approved as a PD therapeutic agent on June 14, 2006.70-71 Rasagiline,
synthesized by Teva Pharmaceuticals, was also approved in 2006 as a PD therapeutic
agent.72-73
By analyzing the chemical structures of these molecules, it can be determined that
a propargyl (triple bond) moiety and a secondary or tertiary amine are present. This
alkyne group allows each compound to form a covalent bond with the N5 atom of flavin
adenine dinucleotide (FAD)74 near the C-terminal region35 on the MAO-B enzyme,
essentially blocking all activity. As the MAO enzymes require FAD as their cofactor,36
this covalent interaction inhibits their proper functions. (A cofactor is a non-protein
molecule required for executing a chemical reaction.75)
Pargyline and selegiline are very simplistic structures with only two extra carbons
in the latter (one being the chiral center with an R-configuration) as the difference
between them.17 Both of these molecules also contain a tertiary amine motif. Rasagiline
(20), on the other hand, possesses a 2,3-dihydro-1H-indene group as opposed to an
ordinary benzene ring.17 This molecule incorporates more lipophilic C-H bonds, but also
possesses hydrogen bond donor capabilities unlike compounds 18 and 19 due to the free
N-H bond in its secondary amine. Rasagiline also possesses more steric hindrance than
compounds 18 and 19, arising from the second cyclic structure on the molecule. Unlike
selegiline’s R chiral center, rasagiline possesses an S stereocenter, while pargyline is
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achiral.17 This indicates that chirality is irrelevant for proper action as an irreversible
MAO-B inhibitor.
In order to avoid the risks posed by completely terminating enzymatic activity,
reversible inhibitors are the ideal class of MAO-B inhibitors. This type inactivates
enzymes without the creation of a covalent bond, allowing for the inhibitors to ultimately
be released after a duration of time.76 As the inhibitor must be bound to stall enzymatic
function, reversible inhibitors only stop the targeted metabolic pathway for as long as the
drug is administered.74 This means that as the concentration of the MAO-B inhibitor in
the body decreases, the levels of dopamine in the body will also decrease accordingly. As
with most therapeutic agents, this simply requires that another dose of the medication
must be taken in order to achieve the desired symptom relief.
Reversible inhibitors of MAO do not cause the same type of cardiovascular toxic
effects as the levels of tyramine are not permitted to increase to the same extent as
compared to an irreversible inhibitor.77 In vivo, tyramine displaces the reversible inhibitor
and becomes metabolized.77 Subsequently, the inhibitor binds once again to the MAO
enzyme and causes the activity to halt.77 In this way, the tyramine substrate is still
degraded, while the levels of the desired neurotransmitters are concurrently increased. 77
Conversely, an irreversible inhibitor would not allow for tyramine to be degraded due to
the formation of the covalent bond with FAD.74
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Two selective reversible inhibitors of MAO-B have been previously utilized.
These molecules, lazabemide (21) and safinamide (22), are structurally much more
complicated than the three propargylated irreversible inhibitors. These compounds have
more highly conjugated systems, with lazabemide exhibiting resonance through its
carbonyl and safinamide possessing two aromatic rings in its structure. Both of these
compounds also contain amide and amine functional groups, three hydrogen bond
donors, and multiple hydrogen bond acceptor sites.
Both lazabemide and safinamide posed potential alternatives to the irreversible
MAO-B inhibitors. Lazabemide was first developed in order to combat PD, Alzheimer’s
Disease (AD), and to aid in smoking cessation.78 As smoking lowers the activity of
MAO-B in vivo, it was hypothesized that the use of this molecule would assist subjects in
weaning off smoking.79 Unfortunately, due to hepatotoxicity,78-79 lazabemide was
discontinued during phase II clinical trials.79
Safinamide (Xadago) was FDA-approved in 2017.80 Patients using safinamide
exhibited improved symptoms for the first 78 weeks.81 Subsequently, increased dosages
of the drug were required for the amelioration of symptoms for moderate to severe
dyskinesia.81 This indicates that tolerance for the drug developed. 81 As the efficacy of this
drug diminishes over time, the synthesis of a more potent therapeutic agent is important
for providing long-term relief of symptoms.
Despite recent progress in synthesizing viable MAOIs, further improvements
could still be made. Currently, MAOIs are not used as the first line of antidepressants due
to the deleterious side effects like hypertensive crisis that can occur.82 Additionally, due
to the potential for increased blood pressure, these molecules are not suitable for
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individuals afflicted with hypertension. As approximately 45 % of all American adults
have high blood pressure,83 108 million Americans83 cannot use MAOIs as PD
therapeutic agents or as antidepressive treatments without a change in diet as this could
elevate the risk of stroke due to hypertensive crisis.63,84 These antidepressants are still
utilized for individuals who have adverse reactions to other medications; 84 therefore,
these still constitute a suitable class of molecules that could be optimized to provide relief
and improve health.
Additionally, these aforementioned undesirable side reactions could be avoided
by utilization of more potent therapeutic agents as less concentration of the drug would
be necessary to ameliorate symptoms. If a smaller dose of the drug is administered, then
the likelihood of undesirable side effects may be decreased. Ideally, more potent specific
reversible MAO-B inhibitors must be synthesized in order to decrease any toxicity risks.
These would subsequently act as more desirable pharmaceuticals to use in addition with
L-dopa for Parkinson’s disease treatments.

1.7. Chalcones as MAO-B inhibitors

One privileged scaffold85-86 currently being investigated for its potential to act as
reversible MAO-B inhibitors is a class of molecules known as chalcones (23).87 These
molecules, like L-dopa, are naturally occurring11,85 and possess the ability to permeate the
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BBB via transport proteins.88 The chalcone scaffold contains an ,-unsaturated carbonyl
group flanked on both sides by aromatic rings, denoted as “A” on the left and “B” on the
right.85 This class of compounds also possesses a myriad of biological activities including
anti-neurodegenerative,89-90 anti-proliferative,86 anti-leishmanial,91 and antifungal.92
Unfortunately, due to their ability to exhibit such a diverse number of biological
properties,86,89-92 this partially limits the capability of these molecules to act as effective
drug agents due to the potential to develop adverse side effects.

Scheme 3: Claisen-Schmidt Condensation of Substituted Chalcones93
As these molecules can be synthesized by a basic Claisen-Schmidt condensation
using dilute sodium hydroxide and ethanol as the base and solvent respectively,93 the
diversification of these compounds can easily be accomplished by merely altering the
substituents present on the two reagents, an acetophenone (24) and an aryl aldehyde (25).
This is illustrated in Scheme 3.93 Since these molecules can be made fairly easily, a large
number of chalcones can be synthesized quickly to create a substantial screening library.
Upon analysis of the biological results, a lead compound can be determined and
optimized for the synthesis of an even more potent therapeutic agent.94 The data obtained
from biological collaborators can then be used to ascertain structure-activity relationships
(SARs) and identify functional groups associated with increasing potency.
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The first reported use of chalcones as MAO inhibitors was 1987.95 In this study
by Tanaka et al., licorice phenolics including isoliquirtigenin (26) were analyzed and
determined to possess inhibitory activity towards rat liver MAO at micromolar
concentrations.95 Specificity towards MAO isoforms was not assessed.95 Therefore, this
examination provided information regarding the MAO inhibitory activity of chalcones,
but did not detail the MAO isozyme that this class of molecules could be optimized for.95
Based on the results of this study, Chimenti et al. evaluated trisubstituted
chalcones predominantly possessing a phenolic functional unit and either an electron
donating group (EDG) or another electron-withdrawing group (EWG) on the A ring in
2009.87 (These compounds incorporated EDGs like methoxy, alkyl, or OCH2Ph
functionalities or EWGs including hydroxyl or fluoro motifs.87) The B ring primarily
incorporated the strongly electronegative atom, chlorine; however, the investigation also
analyzed methyl and methoxy EDGs.87
When evaluating the ability of molecules to act as inhibitors, researchers quantify
the concentration at which 50 % of enzymatic activity is diminished as the IC 50 value.96
As lower concentrations of pharmaceutical agents are desired in order to avoid
toxicological issues, a more potent therapeutic drug will possess a smaller IC 50 value.
Additionally, the aforementioned Italian group evaluated each molecule’s selectivity for
MAO-B as compared to MAO-A.87 They denoted this value as the selectivity index
(SI).87 The SI was determined by calculating the ratio of MAO-A to MAO-B.97 As
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discussed previously, these two isoforms possess different targets;17,46-47 therefore, a
potential drug agent must act specifically on only one of these enzymes as the repression
of the other protein could cause deleterious side effects.

Their results provided important insights regarding the structural moieties that
interacted most favorably with the MAO-B enzyme. Compared to the standard
irreversible inhibitor, selegiline, compounds 27 and 28 both exhibited an approximate 4fold decrease in IC50 value.87 This indicated their potential to act as lead compounds for
further drug development.87 (The IC50 values were 0.02 M, 0.0044 M, and 0.0051 M
for molecules 19, 27, and 28 respectively.87) Additionally, 27 demonstrated about three
times better selectivity than selegiline.87 This irreversible inhibitor possessed an SI of
3,362 while 27 had an SI of 11,364.87 Compound 29 also exhibited submicromolar
activity, but it was almost ten times less potent than 27.87 Based on these results, it can be
posited that the A ring of an improved chalcone molecule must be disubstituted and
contain one hydrogen bond donor and two hydrogen bond acceptors in order to exhibit
the desired activity.
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After analyzing the research investigation from 2009, multiple other studies have
been performed to determine the MAO inhibitory effects of chalcones or chalcone
derived molecules. (These have included methoxychalcones, 97-98 heterocyclic
chalcones,99 and extended chalcones.100) Analogues of this molecular skeleton have also
been previously used as CNS therapeutic drug agents.101-106 A prime example, fluoxetine
(30), known as Prozac, acts as an antidepressant.101-102 Flumazenil (31), Romazicon,103
has been used to reverse the effects of benzodiazepine sedation. 104 Melperone (32) has
been prescribed as an antipsychotic.105-106 Halazepam (33), marketed as Paxipam, is an
anti-anxiety medication.107 Based on the success of these molecules as drug agents, it was
postulated that chalcone derivatives would potentially yield favorable repression of MAO
activity AND would also maintain the ability to pass the BBB.

As each of these aforementioned pharmaceutical agents possess a fluorine atom, a
group in 2015 evaluated methoxychalcones derived from various fluorinated
benzaldehydes.97 The most potent and selective of this class was compound 34 with a Ki
value of 0.22 M and a selectivity index of 19.6.97 A Ki value, similar to an IC50 value,
denotes the concentration of an inhibitor necessary to produce half of the maximum
inhibition.108 Ki denotes binding affinity to the inhibitor; whereas, IC50 describes the
functional strength of the inhibitor as a pharmaceutical agent. 96
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Following this study, Mathew et al. further evaluated disubstituted 4methoxychalcones that incorporated other EWGs (including halogens, nitro groups, and
phenolic structural units) and EDGs (like 4-dimethylamino and 4-methoxy motifs) onto
their B ring in order to assess their MAO-B inhibitory activity.98 In this research
investigation, compound 35 exhibited a Ki value of 0.14 M and an SI of 19.29 as
compared to the Ki value of 0.31 M and SI of 18.10 for selegiline.98

Most recently in 2019, Shalaby et al. evaluated the presence of EWGs on both the
A and B rings.109 Along with these molecules, this group also determined the biological
activities of chalcones incorporating 1,3-benzodioxole (36) or 4-methylsulfonylbenzene
(37) moieties.109 Interestingly, the most potent compound overall was molecule 38 with
an IC50 value of 0.034 M and the most selective of these was compound 39 with an SI
value of 1720.109 This indicates that EWGs may need to be present on both benzene rings
to possess more potent inhibitory properties; whereas, a bulky substituent on ring B may
be required for better specificity.
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In addition to these studies using the exact molecular skeleton, several substituted
chalcone derivatives have been explored. In 2015, Minders et al. evaluated heterocyclic
chalcones that incorporated thiophene (40), pyrrole (41), furan (42) and pyridine (43)
moieties.99 Of the analyzed molecules, the most promising thiophene derivative (44)
exhibited a 67.0 nM IC50 value and a selectivity of 240.99 The most potent compound
incorporating a furan structural motif (45) possessed an IC50 value of 0.174 M; whereas
the best pyrrole derivative (46) inhibited MAO-B at an IC50 value of 0.803 M.99 The
sole pyridine molecule (47) had an IC50 value of 0.330 M.99

Within the last decade, indolyl chalcones have also been assessed for their
repression of MAO-B activity.110 In a study by Sasidharan et al., the indole motif (48)
was incorporated into the A ring and various EDGs and EWGs were utilized on the B
ring to determine which structural units would increase potency.110 According to their
tabulated biological data, compound 49 proved to exhibit the most dramatic MAO-B
inhibitory properties with a Ki value of 10 nM and the greatest specificity (120) for
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MAO-B over MAO-A.110 All of their screened indolyl chalcones possessed inhibition
constants at submicromolar concentrations,110 indicating their potential to act as lead
compounds in future drug development.

The most potent class of chalcone analogues that have been explored are the
extended chalcones. In a study by Desideri et al., it was determined that extended
chalcones with a hydroxyl group on the A ring possessed MAO-B inhibitory activity at
nanomolar concentrations.100 The most notable of these was compound 50 which
exhibited an IC50 value of 4.51 nM for MAO-B activity and an SI of 22,173.100 Even one
of the least potent molecules in the study, compound 51, exhibited an IC50 value of 1.46
M for MAO-B activity and an SI of 68.100 In this investigation, the normal chalcone
scaffold was also evaluated and it was determined that the extended analogues were
significantly more potent than the regular chalcones.100
Certain SARs can be made based upon the previously described compounds. The
majority of the potent molecules possess EWGs on the B ring and at least one EDG on
the A ring.97-100,110 In addition, it can be determined that the extended chalcones also yield
desirable inhibitory characteristics as the most optimized derivatives of both the extended
chalcones AND the indolyl chalcones (which increase the length of the compound
through an additional heterocyclic ring) exhibit MAO-B inhibitory activity at or below 10
nM.100,110 These values are heavily influenced by the substituents utilized in the molecule
as 50 exhibits one thousand times more inhibitory activity than compound 51.100 This
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indicates that the active or allosteric site to which the molecule binds requires an EDG
like 4-methoxy in 50 as opposed to an EWG like 4-chloro in 51.

Based on the chalcone data it also appears that atomic size plays a large role in
activity as well.109 The only difference between molecules 52, 53, and 54 are the
halogens at the 4-position of ring B. Compound 52 exhibited the most potent inhibitory
activity of MAO-B with an IC50 value of 0.043 M; whereas molecules 53 and 54
demonstrated 50 % inhibition at 0.050 M and 0.102 M respectively.109 Therefore, it
can be determined that an increase in the atomic size of the halogen on the B ring
correlates with decreased activity. Interestingly enough, the opposite is true for the A
ring.109 Molecules possessing smaller atoms on ring A yielded less repression of
enzymatic activity, while larger atoms exhibited more inhibitory activity.109

1.8. WSU Approach to the Synthesis of MAOIs
Originally, a library of chalcone compounds was synthesized by the Ketcha Lab
group and analyzed for both MAO-A and MAO-B inhibition in order to determine both
the specificity of these molecules for one isoform over the other and the MAO-B
inhibitory activity of these compounds (Kinstedt, unpublished results). As stated
previously, not only would the ideal molecule exhibit inhibitory effects at a low
concentration, but it would also demonstrate specific repression of MAO-B enzymatic
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function in order to be considered a viable PD therapeutic agent in association with Ldopa.
However, due to the promiscuity of the chalcone scaffold,86,89-92 the SARs derived
from our chalcone studies and from previously published research were then utilized to
create a new flight of compounds using an analogous molecular skeleton, known as
benzylidene oxindoles (BOs), to act as specific MAO-B inhibitors. Benzylidene
oxindoles were evaluated in order to determine if these compounds would exhibit less
deleterious side effects and/or improved potency than chalcones. As these two scaffolds
contain similar structural attributes, it was posited that these two classes of molecules
would be chemically analogous. Therefore, BOs were hypothesized to also reversibly
repress the activity of MAO-B.
In this investigation, it was theorized that one could “scaffold hop” from one
molecular skeleton to another and still exhibit the desired biological activity. Scaffold
hopping is a technique used in lead optimization in which a chemical skeleton,
structurally similar to another scaffold with biological activity, is manipulated in order to
determine if it also possesses the same properties.111 In this case, most of the molecular
structure is conserved, but slight differences exist between the two classes. 111
Additionally, based on the results of both the chalcone and the BO studies, functional
groups could be definitively determined as possessing MAO-B inhibitory activity.
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Figure 6: Scaffold Hopping from Chalcones to Benzylidene Oxindoles
As can be seen in Figure 6, the “jump” from chalcones to benzylidene oxindoles
is not a large one. Both of these classes contain an extended pi system, two aromatic
benzene rings (labeled as ‘A’ and ‘B’), and a conjugated carbonyl. The main differences
between the two molecular skeletons are the amide functional group and the extra five
carbon ring incorporated into the BO scaffold. Unfortunately, due to the increased
number of hydrophobic C-H bonds, the lipophilic character of benzylidene oxindoles is
significantly higher by an approximate 0.57 units as calculated by ChemDoodle.13
The blood-brain barrier (BBB) is formed by tight junctions between brain
endothelial cells (astrocytes and pericytes) along with laminin and collagen. 112 This forms
a tight barrier88 against molecules that do not possess adequate lipophilic character. As
only compounds with log P values between approximately two and three possess the
capability to permeate the BBB,15 the synthesized derivatives of these molecules are
unlikely to exhibit the same permeability as chalcones. However, if more hydrophilic side
groups are incorporated in the B ring, they may still possess the proper lipophilicity to
permeate the BBB.
The synthesis of benzylidene oxindoles (55) is virtually analogous to the
production of chalcones. This class of compounds also requires a Claisen-Schmidt
condensation; however, in this synthesis an aryl aldehyde (benzaldehyde) and an
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oxindole (56) are utilized as reagents. Instead of employing a dilute strong base like
NaOH or KOH as in our chalcone studies,113 a weak base known as piperidine was used.
This entire process is provided in Scheme 4. As the amide N-H bond is partially acidic
due to resonance,114 the weak base piperidine will not strip the hydrogen from the
nitrogen, while a strong base may be able to do so. This removes the potential of
undesirable side reactions that could decrease both the purity and percent yield of the
product.

Scheme 4: Preparation of Substituted Benzylidene Oxindoles
One of the main goals of this investigation was to determine structure-activity
relationships between functional groups and their MAO-B inhibitory activities. In order
to accomplish this objective, the Ketcha Lab group desired to make a comprehensive
library of compounds that would provide information regarding the inhibitory character
of each structural motif without any confounding variables. As the only three analyzed R
groups at the 5’ position of the oxindole were 5-H, 5-F, and 5-Cl, diversification of this
molecular skeleton was accomplished mainly by altering the substituents present on the
reagent benzaldehyde. (Unfortunately, the 5-chlorooxindole reagent is extremely
expensive, so only one molecule was synthesized from this derivative.)
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The unsubstituted versions of the 5-H (57) and 5-F (58) benzylidene oxindoles,
where X is simply a proton, act as controls to compare against the inhibitory activity of
their substituted versions. As the unique functional moieties (ex. 3,4,5-trimethoxy, 2,6difluoro, 4-hydroxy, etc.) incorporated into the substituted analogues of 57-58 can then
be compared to these controls, it can be determined which structural motifs will yield
desirable interactions with the MAO-B enzyme. Additionally, by comparing the 5-H (59),
5-F (60), and 5-Cl (61) benzylidene oxindoles derived from the same benzaldehyde, the
effects of substitution at the C-5’ carbon and atomic size of the halogen can be
determined. Thus, if compounds 60 and 61 are more potent MAO-B inhibitors than
molecule 59, then substitution at the C-5’ position may be critically important. If
compound 61 demonstrates more potent inhibition than 60, then the atomic size may have
a significant impact on suppression of enzymatic activity.
Additionally, several of the motifs we were unable to incorporate into the
chalcone scaffold were able to be integrated into the benzylidene oxindole skeleton.
These fragments included hydroxyl groups and phenols. Phenols are slightly acidic and
can thus be deprotonated using a strong base like NaOH; however, weaker bases like
piperidine are unable to fully deprotonate this slightly acidic proton.115,116 This can be
explained by the difference in pKas.115 A reaction is virtually irreversible if the pKa of
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the acidic reagent is significantly lower than that of the resulting conjugate acid;
however, if the pKas are similar, then the reaction may occur in both directions.115
In the aforementioned case, the pKa of a phenol is approximately 10; whereas, the
pKa of a protonated amine, specifically protonated piperidine in this instance, is about
10.6.116 The small difference in these values indicates that the reaction is generally
reversible and both species would be present at equilibrium. 115 In comparison to
piperidine, the pKa of NaOH’s conjugate acid, water, is approximately 15.7.116 Due to the
significant difference in pKa values, the reaction would generally be irreversible in the
forward direction and the phenol would be deprotonated.115 For this reason, all phenolic
chalcones were unable to be synthesized properly with either base, because the resulting
charged phenoxide would either act as a nucleophile or would cause the product to
remain water-soluble.
Additionally, chalcones derived from vanillin were unable to be synthesized.
Originally, NaOH was utilized as the base; however, the correct molecules were not
made. After subsequent failed attempts using both piperidine as the base and various
protecting groups respectively, the desired compounds were still unable to be formed.
Using piperidine at 90 C, the 4-methoxy-3-hydroxy, 3-hydroxy-4-methoxy, and 4hydroxy motifs could all be incorporated into the benzylidene oxindole scaffold. As these
groups are critically important for many biological properties including MAO-B
inhibitory activity,87,100 this allows for the synthesis of a larger library of molecules with
possibly more potent MAO-B inhibitory characteristics.
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Interestingly, the benzylidene oxindole scaffold (or virtually analogous structural
derivatives) have previously been analyzed for their ability to repress the activity of both
MAO isoforms. In a study by Suthar et al., BOs were evaluated for their potential to act
as antidepressant agents based on their MAO-A inhibitory properties.117 In this study, the
most potent BO, the 4-bromo derivative, possessed a subpar IC50 value of 18.27 M
towards MAO-A.117 This compound demonstrated 1.5 times more inhibitory activity than
the next most improved BO (62) in this study.117 None of the compounds in this
investigation presented activities near that of the standard therapeutic agent used in
research analyses, clorgyline (63), which exhibited an IC50 value of 3.65 M.117
Clorgyline, a selective MAO-A inhibitor118 and antidepressant, was introduced in 1991
and possesses structural characteristics similar to pargyline. 119 (This molecule was later
abandoned due to its dangerous interaction with tyramine. 120) However, the 4-bromo
derivative did possess an IC50 value only 5.1 M larger than moclobemide (64),117 a
reversible inhibitor of MAO-A.121
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Another study by Huang et al. evaluated the structurally analogous 2benzylidene-1-indanone scaffold (65).122 These molecules exhibited inhibition of both
MAO-A and MAO-B with very little selectivity towards one enzyme or the other.122 (The
SI values ranged from 3.50-5.36.122) However, as the amide functionality present in the
BO molecules is lost in this scaffold, there is the potential that the inhibitory activity
and/or selectivity for either MAO isoform will increase in the BOs. Additionally, as both
studies are far from exhaustive, the investigation described herein has the capability to
determine a lead compound for either enzyme AND to shed light onto the structural
moieties important for improved selectivity and potency.
A significant issue to note with benzylidene oxindoles is their tendency to exist as
both E and Z stereoisomers.123 Unlike chalcones, which are predominantly E geometric
isomers due to the large difference in steric hindrance between the cis and trans alkenes,
the E and Z stereoisomers of BOs both possess steric hindrance to some extent.113 The
geometric isomers of both BOs and chalcones are provided in Figure 7. The E isomer of
BOs has interactions between the two aromatic benzene rings. 113 (This undesirable steric
hindrance would be greatly increased if the 5’ position of the oxindole or the C-2 carbon
of the benzaldehyde starting materials were substituted.) Upon analysis of the Z isomer, it
can be determined that any substituent at the C-2 carbon of the benzene ring would
interact with the carbonyl oxygen. This would also potentially yield unfavorable steric
hindrance.
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Figure 7: The Geometric Isomers of Benzylidene Oxindoles and Chalcones113
On the other hand, chalcones have two hydrogen atoms on their double bonds as
implied by Figure 7. When these molecules are oriented as the E isomers, the carbonyl
and the B ring are as far apart as possible and minimal steric hindrance exists. If the
compounds are instead oriented in their Z configurations, a significant amount of steric
hindrance will arise due to the interactions of the carbonyl and ring B. For this reason, the
E isomers of chalcones will predominantly be synthesized as compared to the Z isomers.
Because enzymes are generally specific to one configuration as opposed to both
3-D orientations, it is necessary to accurately determine which geometric isomer
produces the desired inhibitory properties. (As an example, human enzymes only catalyze
L-amino acids and not D-amino acids.31) For this reason, the ratio of Z:E stereoisomers is
generally represented when discussing derivatives of this scaffold.123 Unfortunately, this
poses a slight issue for this study as any suppression of MAO-B activity could not be
specifically attributed to one geometric isomer over the other for those molecules
possessing a mixture of stereoisomers.
Luckily, only one compound described in this study, molecule 98, significantly
presented as both geometric isomers. Due to the difficulty in separating these E and Z
isomers, this was unable to be completed. Therefore, inhibitory activity could not be
attributed to one specific geometric isomer in this case. This also poses an issue in drug
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design as the inactive stereoisomer has the potential to cause harmful side effects in the
body. This study is relevant, however, as it provides information regarding functional
groups that improve MAO inhibitory properties. Additionally, only one of the
synthesized derivatives was determined to be potentially problematic.
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2. Results and Discussion
In this research investigation, thirty-six molecules were synthesized in order to
determine their potential to act as MAO-B inhibitors. Twenty-three compounds (66-88)
were derived from indolin-2-one, twelve (89-100) from 5-fluoroindolin-2-one, and one
(101) from 5-chloroindolin-2-one. Medicinal chemistry requires an understanding of
previous research findings and justifications as to why molecules in a particular screening
library are chosen for biological testing. For this reason, the rationales behind the
synthesis of each compound in this study are provided herein.

2.1. Benzylidene Oxindoles Derived from Indolin-2-one
The first six molecules (66-71) were synthesized to evaluate the effect of methoxy
substituents on MAO-B inhibitory activity. The subsequent two (72-73) were made in
order to establish how vanillin and isovanillin derived compounds would act against the
desired target. Molecule 74 was evaluated to determine how an electron-withdrawing
hydroxyl group would affect activity. The following molecules (75-79) were made to
ascertain information regarding the potency of various fluorinated compounds as MAO-B
inhibitors. The two molecules derived from 4-nitrobenzaldehyde (80) and 2nitrobenzaldehyde (81) were synthesized in order to evaluate the effects of a nitro group
against the target.
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Compounds 82-84 were synthesized in order to determine how the extension of
the scaffold would affect inhibitory properties. Molecule 85 was analyzed in order to
evaluate how the simplest electron-donating group, a methyl motif, would alter biological
activity. Compounds 86 and 87 assessed how the atomic size of electron-withdrawing
groups, in this case halogens, would influence activity. Molecule 88 was synthesized to
act as a negative control for the study. Several of the 5-fluoroindolin-2-one analogues of
molecules 66-88 were then evaluated in order to determine if the incorporation of a
fluorine atom at the C-5’ position of the A ring would increase potency. Additionally, the
non-fluorinated derivative of compound 96 was unable to be synthesized; however, this
molecule was included in the study to assess whether the inclusion of a 2-hydroxyl (96)
substituent yielded enhanced activity as compared to a 4-hydroxyl (95) motif.
As stated previously, the first six molecules (66-71) were synthesized in order to
evaluate the position and number of methoxy groups that would yield the most potent
MAO-B inhibitor. Compound 66 was synthesized as the indolyl chalcone derivative
incorporating this 4-methoxy motif possessed the third highest selectivity index (10.91)
and a Ki value of 0.11 M for MAO-B.110 Additionally, every compound derived from 4methoxyacetophenone exhibited submicromolar Ki values against MAO-B.98 Even the
simplest unsubstituted 4-methoxychalcone demonstrated a selectivity index of 5.07 and a
Ki value of 0.70 M.98 It was posited that these trends would remain conserved when this
fragment was incorporated into the benzylidene oxindole scaffold. Molecule 67 was then
synthesized to determine how the 2-methoxy substitution pattern would alter biological
activity. As the 4-methoxy and 3-methoxychalcones had previously been shown to
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demonstrate submicromolar Ki values in recent literature,97-98 the 2-methoxy derivative
was hypothesized to possess analogous properties.
The substitution patterns for the final four molecules possessing methoxy motifs
(68-71) have not been thoroughly analyzed in literature for their MAO-B inhibitory
activities. These four compounds were evaluated in order to determine how the number
of methoxy groups incorporated into the molecule would affect potency. Compounds 68
and 69 were synthesized to determine how the addition of two methoxy groups, one with
a 3,4-dimethoxy unit (68) and the other with a 2,5-dimethoxy motif (69), on the B ring
would affect MAO-B inhibitory activity.
The final two molecules, possessing a 3,4,5-trimethoxy group (70) and a 2,4,6trimethoxy fragment (71) respectively, were subsequently evaluated for their biological
properties. Compounds 66, 68, and 70 could be directly compared as each increased by
only one methoxy group from the first compound (66) to the third (70). This allows for a
direct determination of the inhibitory effects of incorporating additional methoxy
moieties as each molecule retains the substitution pattern of the previous compound and
only adds one extra methoxy group. Interestingly, previous literature regarding the 2,4,6trimethoxy motif on the B ring of chalcones has shown potent and selective MAO-A
inhibitory activity.109 As derivatives of the benzylidene oxindole scaffold have also been
described to possess MAO-A inhibitory properties,117 compound 71 could serve as a
potent inhibitor of this isozyme.
The following two molecules (72-73) were synthesized due to the various
biological characteristics associated with vanillin chalcone derivatives. These include
anticancer,124 antibacterial,125 antimicrobial,125 and anti-inflammatory properties.125 As
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the vanillin moiety was present on the B ring of these evaluated compounds,124-125 it was
posited that analogous activity would be present when incorporated into the same ring of
the benzylidene oxindole scaffold as in molecule 72. The isovanillin derivative (73),
additionally shown to possess anticancer properties, 124 differs simply in the arrangement
of its hydroxyl and methoxy fragments. (Vanillin possesses a 4-hydroxyl motif and a 3methoxy substituent;126 whereas, isovanillin incorporates a 4-methoxy group and a 3hydroxyl moiety.127) These analogous substituents were hypothesized to possess similar
potencies against MAO-B. Additionally, the incorporation of both a 2-hydroxyl and 4methoxy substituent into a chalcone molecule yielded an IC50 value of 0.0044 M and a
selectivity index of 11,364 for MAO-B in Chimenti et al.’s 2009 study.87 Due to the high
specificity and potency exhibited by a chalcone molecule possessing the same
substituents in different positions, these were included in the BO scaffold in order to
determine if analogous properties were observed. The more potent substituent pattern
would also be determined subsequent to the evaluation of both compounds.
Compound 74 was synthesized to determine the MAO-B inhibitory property of a
single hydroxyl group in the para position of the B ring of a benzylidene oxindole. When
this alcohol substituent was present on the B ring of a chalcone, the molecule possessed a
subpar IC50 value of 13.6 M against MAO.95 A comparison of this value with the
determined IC50 from this study would, therefore, provide a way to directly evaluate the
potency of these two scaffolds. In the study by Mathew et al. in 2017, the presence of a 4hydroxyl group yielded a low selectivity index (2.65) and a modest Ki value (1.78 M)
against MAO-B when paired with an EDG on the A ring.98 The most analogous scaffold,
the indole-based chalcone, demonstrated a Ki value of 0.35 M and a selectivity index of
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5.66 for MAO-B when a hydroxyl group was incorporated.110 A direct comparison can
also be made against compound 72 in order to determine if both an EWG and an EDG
must be present on the B ring, or if simply an EWG can be used to effect MAO-B
inhibition.
The next subset of synthesized molecules (75-77) evaluated the role of fluorine
substituents on MAO-B inhibition in BOs. Compounds 75 and 76 were assessed to
determine the inhibitory effect of one fluorine atom on ring B. Molecule 75 incorporated
a 4-fluoro motif onto ring B of the BO scaffold. In the indole chalcone molecular
skeleton, this structural unit exhibited an SI value of 9.66 and a Ki value of 0.30 M for
MAO-B.110 Due to the similarities between the indole chalcone and BO scaffolds, it was
hypothesized that analogous potency would be exhibited by 75. Additionally, the 4-fluoro
moiety possessed the second highest SI index for MAO-B as compared to the various
other fluorine substituent patterns.97 That particular study incorporated a 3-methoxy
fragment on ring A of the chalcone derivatives.97 Compound 76 was synthesized to
evaluate the effect of a fluorine atom on the C-2 carbon of a BO. The biological activity
was expected to be virtually analogous to molecule 75 based upon the results from the
previously described study.97
Compound 77 was then evaluated to determine how the incorporation of multiple
fluorine atoms on the B ring would impact MAO-B inhibitory activity. A study by
Minders et al. described potent MAO-B inhibitory characteristics with the incorporation
of two halogens; however, the heterocyclic chalcones evaluated in that study were
structurally less analogous to BOs as compared to normal chalcones.99 Ideally, regardless
of this difference in molecular skeletons, a difluorinated BO molecule should similarly
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increase MAO-B inhibition. A direct comparison between compounds 76 and 77 would
provide strong evidence regarding whether the presence of one or two fluorine atoms
would be more effective as an MAO-B inhibitor.
The following molecules (78-79) were made to assess the effects of the 4trifluoromethyl (78) and 2-trifluoromethyl (79) substituents on their respective B rings in
BOs. For the indolyl chalcone scaffold, the incorporation of a 4-trifluoromethyl moiety
yielded a slightly lower SI but 1.5 times smaller Ki value as compared to the 4-fluoro
derivative.97,110 The 4-trifluoromethyl functional unit is also potent against MAO-B in the
chalcone molecular skeleton.109 This motif demonstrated the highest selectivity and
lowest Ki value for MAO-B when paired with the electron-donating 3-methoxy group on
ring A.97 This structural unit incorporated into ring A also exhibits increased selectivity
and submicromolar IC50 values when paired with a 4-dimethylamino moiety on ring B.109
The 2-trifluoromethyl substituent was similarly evaluated with a 3-methoxy group on the
A ring of a chalcone molecule.97 This compound possessed the least potent MAO-B
inhibitory activity and the smallest SI index of all molecules evaluated; 97 therefore,
molecule 79 was posited to be the least effective of molecules 75-79.
The nitro derivatives (80-81) were then synthesized to evaluate this EWG’s effect
on MAO-B inhibition. Based on the data from the indolyl chalcones, little selectivity is
observed when the 4-nitro group is incorporated into ring B.110 This lack of specificity for
the MAO-B isoform is undesirable as nonselective MAOIs often have dangerous side
effects.53-55 Previous evaluations with the chalcone scaffold have also provided similarly
low selectivity towards the desired isozyme.98 Interestingly, one evaluation of 4-nitro
substituents on ring B paired with chlorine and fluorine respectively on the C-4’ position
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of ring A exhibited some of the highest selectivity indices of the synthesized
compounds.109 These also exhibited IC50 values of 34.0 nM for the chloro derivative and
69.0 nM for the fluoro derivative against MAO-B.109 As these three studies reported
completely different values for nitro groups,98,109-110 the inclusion of this fragment into
the BO scaffold was deemed necessary. Molecule 81 was then evaluated to determine if
the 2-nitro group would be more potent than the 4-nitro substituent.
Compounds 82 to 84 were then evaluated in order to determine how the molecular
length would affect MAO-B inhibitory properties. Molecule 82 was made due to the
potent activity of the 4-dimethylamino unit in both simple and indolyl chalcones.98,109-110
When this motif was present on the B ring of simple chalcones, the selectivity index
increased significantly for MAO-B inhibition regardless of whether an EDG or an EWG
was present on the A ring.98,109 Additionally, when this structural unit was paired with the
4-methoxy functional group on the A ring, the lowest Ki and highest SI values were
observed in the study.98 In the indolyl chalcones, the 4-dimethylamino fragment yielded a
subpar SI of 5.33;110 however, the Ki value remained virtually analogous to the Mathew et
al. study.98,110 As extended chalcone derivatives have demonstrated improved potency as
compared to simple chalcones,100 compound 83 was synthesized in order to determine if
the 4-(dimethylamino)cinnamaldehyde derivative would exhibit increased potency as
compared to molecule 82. As the trend is present for chalcones, it was hypothesized that
this would also remain valid for BOs. Molecule 84 was then made in order to assess
whether or not naphthaldehyde could be substituted for the cinnamaldehyde reagent as
the method of extension. This compound could then be compared to molecule 66 to
determine how the extra aromatic ring impacted MAO-B inhibition.
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The subsequent compound, 85, evaluated the effect of a simple electron-donating
4-methyl group on ring B. When this motif was incorporated into the indolyl chalcone
scaffold, the SI and Ki values were determined as 10.91 and 0.11 M respectively.110
Interestingly, this moiety was the second most selective for MAO-B in this study.110 This
structural unit was also assessed with a 4-methoxy substituent on the A ring in simple
chalcones and a significant SI value of 5.92 was determined; however, the 0.49 M Ki
value was far less potent than several other motifs.98
The following two molecules (86-87), derived from indolin-2-one, were
synthesized in order to evaluate the effects of atomic size on MAO-B inhibition. Both
simple and indolyl chalcones demonstrated trends associated with the size of the halogen
added to ring B.98,110 Upon evaluation of the indolyl chalcone study, it can be determined
that the 4-bromo substituent exhibited the largest SI value (120) as compared to the 4chloro (3.57) and 4-fluoro (9.66) derivatives.110 Additionally, the 4-bromo substituent
was twenty-eight and thirty times more potent than the respective 4-chloro and 4-fluoro
derivatives.110 When paired with a 4-methoxy fragment on the A ring, the simple
chalcone possessing a 4-bromo group was significantly more potent than the 4-chloro
motif on ring B.98 Based on these results, it was expected that molecule 86 would act as
an improved MAO-B inhibitor when compared to 75 and 87.
The final indolin-2-one derivative (88) was made in order to act as a negative
control. The unsubstituted B ring demonstrates a high SI value for both simple and
indolyl chalcones;98,110 however, the Ki value is significantly improved for the indolyl
derivative.98,110
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The chemical structures, log P values, melting points, and absolute configurations
for all synthesized benzylidene oxindoles derived from indolin-2-one are presented in
Table 1.

Table 1: Benzylidene Oxindoles Derived from Indolin-2-one
Name

Compound

Log P

Melting

Literature

Configuration

Point

Melting Point

(Z:E)

4.78

156-157 °C

158-159 °C128

0:100

4.33

215-217 °C

221-222 °C128

0:100

4.40

244-246 °C

239-242 °C129

100:0

4.25

197-198 °C

189-192 °C128

0:100

66
TK-8-77

67
TK-7-195 T

68
TK-8-29 T

69
TK-8-109 R
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70
4.05

196-198 °C

189-191 °C130

100:0

4.59

193-194 °C

188 °C131

100:0

4.08

220-222 °C

226-227 °C132

100:0

4.08

174-177 °C

173-176 °C128

0:100

4.43

>250 °C

255 °C133

0:100

4.58

186-188 °C

194-196 °C129

0:100

TK-7-1 T

71
TK-13-81 R

72
TK-7-131 T

73
TK-7-143 R

74
TK-8-89 R

75
CF-2-8
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76
4.58

223-225 °C

218-220 °C128

0:100

4.74

222-225 °C

no lit. mp

100:0

5.34

200-203 °C

186-189 °C128

100:0

5.34

165-167 °C

175-177 °C128

100:0

3.96

245-247 °C

224-225 °C134

100:0

3.96

234-239 °C

234-235 °C132

100:0

TK-7-187 R

77
MVP-1-5

78
TK-7-163 R

79
TK-7-171

80
MVP-1-67 T

81
TK-8-21 R
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82
5.05

225-226 °C

225-232 °C134

100:0

5.32

214-216 °C

no lit. mp

0:100

5.60

236-240 °C

no lit. mp

100:0

4.64

186-201 °C

199-200 °C128

0:100

5.22

187-188 °C

191-192 °C132

0:100

TK-7-61 T

83
TK-8-81 T

84
TK-8-37 T

85
TK-8-101 R

86
TK-11-63 R
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87
5.04

185-189 °C

189-191 °C128

0:100

4.42

166-167 °C

179-180 °C128

0:100

TK-13-61 R

88
TK-7-127
The log P values were determined by ChemDoodle.13

2.2. Benzylidene Oxindoles Derived from 5-Fluoroindolin-2-one
Compounds 89-100 were synthesized in order to determine if the addition of an
electron-withdrawing motif on the A ring (specifically a fluorine atom on the C-5’
carbon) would increase MAO-B inhibitory activity as compared to the unsubstituted
versions. (The only exception is compound 96. This molecule was unable to be made as
primarily one isomer in the unsubstituted analogue.) Interestingly, based upon the study
by Shalaby et al., it appears that the incorporation of a halogen with a smaller atomic size
(chlorine in their analysis) paired with a 4-dimethylamino moiety on the B ring of the
chalcone scaffold yields a high selectivity index and a submicromolar IC 50 value for
MAO-B.109 As an increase in conjugation has also provided improved MAO-B inhibitory
activity at nanomolar concentrations,100 compounds 99 and 100 were posited to possess
potent desired activity. Specifically, molecule 100 should demonstrate the most
substantial inhibitory characteristics.
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Additionally, one study showed that a halogen with a larger atomic size on the A
ring paired with a 4-nitro group on ring B of a chalcone also possessed a large SI and a
submicromolar IC50 value.109 Thus, molecule 98 was hypothesized to possess significant
activity towards MAO-B.
The last compound of interest in this series is molecule 93. Chalcones possessing
a halogen on the A ring and a 2,4,6-trimethoxy motif on the B ring demonstrated high
selectivity and low IC50 values for MAO-A;109 therefore, molecule 93 was expected to
function as a potent antidepressant. Previous research has also depicted BOs as
possessing MAO-A inhibitory activity,117 which furthers the aforementioned notion.
The chemical structures, log P values, melting points, and absolute configurations
for all synthesized benzylidene oxindoles derived from 5-fluoroindolin-2-one are
presented in Table 2.

Table 2: Benzylidene Oxindoles Derived from 5-Fluoroindolin-2-one
Name

Compound

Log P

Melting

Literature

Configuration

Point

Melting Point

(Z:E)

4.92

200-202 °C

no lit. mp

100:0

4.49

225-226 °C

no lit. mp

0:100

89
TK-8-169

90
TK-8-1 T
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91
4.41

209-214 °C

no lit. mp

0:100

4.75

243-248 °C

194-196 °C135

100:0

4.75

215-217 °C

no lit. mp

100:0

4.24

238-242 °C

no lit. mp

0:100

4.60

>250 °C

no lit. mp

0:100

4.60

197-200 °C

no lit. mp

0:100

TK-8-113 R

92
TK-12-187 T

93
TK-7-183 R

94
TK-7-139

95
TK-8-93 R

96
TK-8-97 R
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97
4.74

132-135 °C

no lit. mp

0:100

4.12

261-266 °C

no lit. mp

30:70

5.21

258-260 °C

no lit. mp

0:100

5.48

254-255 °C

no lit. mp

0:100

TK-7-191

98
MVP-1-45 T

99
TK-7-67 T

100
TK-8-85 T

The log P values were determined by ChemDoodle.13

2.3. Benzylidene Oxindole Derived from 5-Chloroindolin-2-one
The final compound (101) evaluated in this study possessed a 4-methoxy group
on the B ring of the BO scaffold and a chlorine atom on the C-5’ carbon. This molecule
was synthesized in order to determine the effects of atomic size on the A ring. When
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compared with the biological activities of molecules 66 and 89, the necessary size of the
halogen on the A ring can be ascertained. If compound 66 provided optimized results,
then the A ring should remain unsubstituted upon further drug development. However, if
the molecules possessing fluorine (89) or chlorine (101) atoms respectively on the C-5’
carbon were more potent, then these motifs should be incorporated into future BOs to
synthesize better therapeutic agents.

The chemical structure, log P value, melting points, and absolute configuration for
the synthesized benzylidene oxindole derived from 5-chloroindolin-2-one is presented in
Table 3.

Table 3: Benzylidene Oxindole Derived from 5-Chloroindolin-2-one
Name

Compound

Log P

Melting

Literature

Configuration

Point

Melting Point

(Z:E)

168-170 °C

257-260 °C135

0:100

101
5.38
TK-7-109 R

The log P value was determined by ChemDoodle.13
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3. NMR Results
NMR spectra of several potential MAO-B inhibitors are presented in this section.
The first molecule, compound 82, provides an example of a Z stereoisomer. (As fifteen of
the molecules in this study were determined to be or possess Z stereoisomers, it was
deemed necessary to include at least one of these compounds.) Molecule 82 was also
included in order to elucidate DEPT-135 13C-NMR spectra and their usefulness in
confirming molecular structure. Compounds 86, 87, and 75 were described to provide
information regarding how electronegativity affects the locations of signals observed in
NMR spectra. Additionally, molecule 75 was selected to provide details regarding the
unique splitting observed when fluorine atoms are incorporated into a compound. (As this
alters both 1H-NMR and 13C-NMR spectra, the splitting patterns for each are described
herein.) Molecule 95 was chosen in order to describe how hydroxyl groups appear in 1HNMR and to give a method for the determination of their chemical shifts using D2O. It
was also included in order to provide the splitting patterns for the protons derived from
the 5-indolin-2-one reagent. The 13C-NMR peaks in this section were predicted based on
an NMR predicting database (nmrdb.org.)

3.1. 4-Dimethylamino Motif
3.1.1. 1H-NMR Spectrum
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The first chosen molecule, compound 82, provides a simplistic 1H-NMR spectrum
for the evaluation of each proton in the molecule. This compound possesses nine unique
protons. The sole hydrogen signal present in the aliphatic region (a) is representative of
the hydrogens in the 4-dimethylamino motif. The remaining eight signals (b-i), located
between 6.76 and 10.47 ppm, represent the six unique aromatic protons (b, c, f, g, h, and
i), the vinyl proton (d), and the remaining amide N-H functionality (e) as shown in
Figure 8. The coupling constants in this molecule adhere to the normal values expected
from benzene: J = 0-1.5 Hz for para coupling, J = 1-3 Hz for meta coupling, and J = 6-10
Hz for ortho coupling.136

Figure 8: The 1H-NMR of Compound 82 in DMSO-d6
The most downfield singlet, present at 10.47 ppm, represents the N-H bond of the
amide unit and is labeled as e. The aromatic region shows the seven unique protons
located between 6.76 and 8.45 ppm. The most downfield signal in the aromatic region, a
doublet centered at 8.45 ppm, is denoted as c and represents the two equivalent protons at
C-2 and C-6 of the benzylidene oxindole molecule. Splitting (J = 9.1 Hz) occurs due to
the proton at b. The singlet at 7.63 ppm, labeled as d, represents the vinyl proton. The
doublet labeled as f, centered at 7.61 ppm, represents the proton at the C-4’ position.
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Splitting (J = 9.2 Hz) occurs due to proton at g. This coupling constant is rather large
based upon the splitting patterns from the protons at the 5’, 6’, and 7’ positions; however,
it likely results due to the overlap between this signal and the peak for the vinyl proton. In
addition, based on the splitting patterns from the two triplet of doublets signals, there
should also be a smaller coupling constant of approximately J = 1.1 Hz present due to
meta-coupling with the proton at h, yielding a doublet of doublets. This is not observed.
The triplet of doublets centered at 7.12 ppm, labeled as g, represents the proton at
the C-5’ position derived from the oxindole reagent. Splitting (J = 1.1 Hz) occurs due to
the proton labeled as i and the two nonequivalent protons (f and h) adjacent to g (J = 7.6
Hz). The most upfield triplet of doublets, located at 6.94 ppm and denoted as h,
represents the proton at the C-6’ carbon of the final product. Splitting (J = 1.1 Hz) occurs
due to the proton at f and the two nonequivalent protons ortho to the proton at h (J = 7.6
Hz) which are labeled as g and i. The next most downfield signal is a doublet centered at
6.80 ppm and is labeled as i. This represents the proton at the C-7’ position. Splitting (J =
7.5 Hz) occurs due to the proton at h. As with the proton at f, this doublet should also be
a doublet of doublets due to meta coupling. There should be an expected coupling
constant of approximately J = 1.1 Hz due to the proton at g. The last signal in the
aromatic region is a doublet at 6.76 ppm, denoted as b, that represents the two equivalent
protons at the C-3 and C-5 carbons. Splitting (J = 9.2 Hz) occurs due to the equivalent
protons labeled as c.
The final relevant signal in the aliphatic region is the singlet at 3.03 ppm, labeled
as a, that represents the six equivalent protons in the dimethylamino motif. The signal,
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labeled as water in Figure 8, represents residual water that occurs at 3.33 ppm when
DMSO-d6 is utilized as the solvent.137
The locations of the vinyl proton and the protons at the C-2 and C-6 carbons
allow for the absolute determination of the geometric isomer. The vinyl proton is more
deshielded (and thus shifted farther downfield) due to the proximity of the carbonyl at the
C-2’ position in the E isomer.138 Conversely, the ortho-benzylidene protons, those
represented as c in the molecule in Figure 8, experience a downfield shift in the Z isomer
due to the carbonyl. As a result, the protons at the C-2 and C-6 carbons are represented
by peaks in the ranges of 7.85-8.53 ppm for the Z isomer and 7.45-7.84 ppm for the E
isomer.138-139 Additionally, the vinyl proton occurs around approximately 7.84 ppm in the
E isomer and 7.55 ppm in the Z isomer when DMSO-d6 is used as the solvent.138,140 This
intuitively makes sense as the proton in the Z isomer is farther from the carbonyl while
the proton is closer to the carbonyl in the E conformation as shown in Figure 9.

Figure 9: Proximity of Groups to the Carbonyl Oxygen of the Oxindole138
Due to the location of the C-2 and C-6 protons and the vinyl proton in Figure 8,
the absolute determination of this molecule can be assigned as Z.138-140 In this case, the
C-2 and C-6 protons are present at 8.45 ppm, which falls between the 7.85-8.53 ppm
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range. This is indicative of the Z isomer.138-139 Additionally, the location of the vinyl
proton at 7.63 ppm aligns more with the value representative of the Z isomer.138,140

3.1.2. 13C-NMR Spectrum
The 13C-NMR of compound 82 is provided in Figure 10. The most downfield
peak, present at 168.09 ppm and labeled as n, represents the C-2’ carbon derived from the
oxindole reagent. This is the carbonyl carbon of the amide functional group. It falls into
the representative 160-180 ppm range.141 The signal at 152.18 ppm, denoted as b,
represents the C-4 carbon. This peak is shifted downfield due to the proximity of the
nitrogen of the 4-dimethylamino structural unit. The peak at 139.95 ppm, labeled as m,
represents the carbon at the 7’a position. The downshield shift of this aromatic carbon is
due to the proximity of the nitrogen of the amide functional group. The peak at 138.39
ppm represents the -carbon in the ,-unsaturated carbonyl unit. It is labeled as f in
Figure 10. The next most downfield signal, labeled as d and at 135.15 ppm, represents
the two chemically equivalent carbons at C-2 and C-6. The peak at 127.41 ppm, denoted
as g, represents the -carbon in the ,-unsaturated carbonyl. The signal at k, present at
126.57 ppm, represents the C-6’ carbon. The next most downfield peak, labeled as e at
122.54 ppm, represents the C-1 carbon.
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Figure 10: The 13C-NMR of Compound 82 in DMSO-d6
The signal at 121.00 ppm, denoted as i, represents the C-4’ carbon derived from
the oxindole reagent. The peak at 120.77 ppm, labeled as h, represents the C-3’a carbon.
The signal at 118.82 ppm, denoted as j, depicts the C-5’ carbon. The carbon at 111.50
ppm, labeled as c, represents the two equivalent carbons at C-3 and C-5. The most upfield
signal in the aromatic region, located at 109.32 ppm and labeled as l, represents the C-7’
carbon of the benzylidene oxindole.

3.1.3. DEPT-135 13C-NMR Spectrum

The sole aliphatic peak, labeled as a, is overshadowed by the DMSO-d6 peak in
this spectrum. In order to determine the chemical shift, a DEPT-135 was performed and
the results are provided in Figure 11. A DEPT-135 provides the following information:
CH and CH3 signals are represented as positive and CH2 peaks are negative.142
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Figure 11: The DEPT-135 13C-NMR of Compound 82 in DMSO-d6
As expected, only eight carbons are present in the DEPT-135. Because no
methylene groups are present in the molecule, each is represented as a positive peak. As
both the spectra provided in Figures 10 and 11 are run in DMSO-d6, the chemical shifts
of the peaks are relatively conserved. This allows for facile determination of each carbon.
The most downfield peak, present at 138.41 ppm and labeled as d, represents the
-carbon in the ,-unsaturated carbonyl. The peak at 135.16 ppm, denoted as c,
represents the two chemically equivalent carbons at C-2 and C-6. The peak at 127.41
ppm, labeled as g, represents the C-6’ carbon derived from the oxindole reagent. The
signal at 121.00 ppm, denoted as e, represents the C-4’ carbon of the benzylidene
oxindole product. The peak at 118.84 ppm, labeled as f, represents the C-5’ carbon. The
second most upfield signal in the aromatic region, labeled as b and at 111.49 ppm,
represents the C-3 and C-5 carbons derived from the benzaldehyde reagent. The final
aromatic peak, denoted as h at 109.32 ppm, represents the C-7’ carbon. The sole peak in
the aliphatic region, labeled as a at 40.06 ppm, represents the two equivalent carbons
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present in the 4-dimethylamino motif. DMSO-d6 is not present in the DEPT-135,
allowing for the determination of the chemical shift of this carbon.

3.2. Electronegativity Effects
In order to show the effects of electronegativity on both 1H-NMR and 13C-NMR
spectra, the next compounds that will be described are the products derived from the 4bromobenzaldehyde (86), 4-chlorobenzaldehyde (87), and 4-fluorobenzaldehyde (75)
respectively. The incorporation of bromine and chlorine atoms yields standard splitting in
1

H-NMR and 13C-NMR spectra; however, more complex splitting is observed with the

introduction of a fluorine molecule. For the former two compounds, a generic pair of
doublets will be observed in the 1H-NMR. This multiplicity will not be observed in the
fluorine derivative. Additionally, in the 13C-NMR for the fluorinated molecule, splitting
of four carbons into doublets rather than the generic singlets observed in the other two
13

C-NMRs will be present. A more in-depth discussion will be provided later.

3.3. 4-Bromo Motif
3.3.1. 1H-NMR Spectrum
The 1H-NMR of compound 86, provided in Figure 12, depicts the eight unique
hydrogens present in the molecule. The proton bonded to the nitrogen atom of the amide
functional group is represented as a singlet and labeled as h at 10.64 ppm. The seven
hydrogens present in the aromatic region (a-g) represent the six aromatic protons and the
vinyl proton (c). The most downfield peak, a doublet labeled as b at 7.72 ppm, represents
the protons on the C-2 and C-6 carbons. Splitting (J = 8.5 Hz) occurs due to the proton
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denoted as a. As this peak appears between the 7.45-7.84 ppm range, this compound is
determined to be the E isomer.138-140 The next most downfield peak at 7.65 ppm, labeled
as a, represents the two chemically equivalent protons at C-3 and C-5. Splitting (J = 8.4
Hz) occurs due to the proton denoted as b.

Figure 12: The 1H-NMR of Compound 86 in DMSO-d6
The singlet at 7.56 ppm, labeled as c, represents the vinyl proton in the product.
This peak is much closer to the value observed for a Z isomer, yielding slight ambiguity
in the results. As the vinyl proton is generally used for assignment when the C-2 and C-6
carbons are substituted,138,140 and not when unsubstituted as in this instance, the
designation as the E isomer is likely determined as correct. The next most downfield
peak, a doublet labeled as g at 7.48 ppm, represents the proton bonded to the C-7’ carbon.
Splitting (J = 7.7 Hz) occurs due to the proton labeled as f. Additional splitting is
expected to be observed due to the meta coupling with the proton at e, but it is not present
in this spectrum.
The next most downfield signal, a triplet of doublets at 7.24 ppm labeled as f,
represents the hydrogen atom at the C-6’ carbon. Splitting (J = 1.1 Hz) is observed due to
the meta coupling with the proton denoted as d and the two nonequivalent hydrogens
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present at e and g (J = 7.7 Hz). The next most downfield peak, an apparent doublet with
indiscernible splitting patterns, is located at 6.88 ppm and denoted as d. Splitting (J = 7.7
Hz) occurs due to the proton at e. In addition to this ortho coupling, splitting due to the
proton at the meta position (f) would have been expected. This would have an
approximate J value between 1-3 Hz.136 The most upfield signal, a triplet of doublets at
6.85 ppm labeled as e, represents the proton at the C-5’ carbon of the oxindole moiety.
Splitting (J = 1.1 Hz) occurs due to the hydrogen at g and the two nonequivalent protons
at f and d (J = 7.6 Hz).

3.3.2. 13C-NMR Spectrum
The 13C-NMR for compound 86 is provided in Figure 13. Thirteen unique carbon
signals are present, confirming the identity of the molecule. The most downfield peak,
labeled as m at 168.91 ppm, represents the carbonyl carbon of the amide functional
group. The next most downfield singlet at 143.53 ppm, denoted as l, represents the C-7a’
carbon. The peak at 134.78 ppm, labeled as e, represents the -carbon in the ,unsaturated carbonyl unit. The next most downfield peak, labeled as f at 134.16 ppm,
represents the -carbon of the ,-unsaturated carbonyl. The peak denoted as b at 132.23
ppm represents the C-3 and C-5 carbons. The signal at 131.76 ppm, labeled as c
represents the C-2 and C-6 carbons. The peak present at 130.84 ppm, denoted as c,
represents the C-1 carbon.
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Figure 13: The 13C-NMR of Compound 86 in DMSO-d6
The peak at 128.66 ppm, labeled as j, represents the C-6’ carbon. The next most
downfield signal, a singlet at 123.33 ppm denoted as h, represents the C-4’ carbon. The
peak at 122.95 ppm, labeled as a, represents the C-4 carbon attached to the bromine
atom. The signal at 121.69 ppm, denoted as i, represents the C-5’ carbon derived from the
reagent indolin-2-one. The next most downfield peak, labeled as g at 121.11 ppm,
represents the C-3a’ carbon. The most upfield singlet, denoted as k at 110.68 ppm,
represents the C-7’ carbon.

3.4. 4-Chloro Motif
As chlorine is slightly more electronegative than bromine, it would be expected
that a farther downfield shift would be present for both protons and carbons (in their
respective 1H-NMR and 13C-NMR spectra) in close proximity to this electronegative
element. This trend generally occurs because decreased electron density yields a
downfield shift.143 As compared to compound 86, the remainder of the peaks not
representing elements near the chlorine atom should remain relatively conserved. The
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only significant differences would be observed in the protons derived from the
benzaldehyde reagent.
3.4.1. 1H-NMR Spectrum
The 1H-NMR of compound 87 is provided in Figure 14. The most downfield
peak, a singlet at 10.64 ppm labeled as h, represents the hydrogen bonded to the nitrogen
atom of the amide functional group. The next most downfield signal, a doublet centered
at 7.72 ppm and labeled as b, represents the two equivalent protons at the C-2 and C-6
carbons. As this chemical shift falls within the 7.45-7.84 ppm range, the molecule is
determined to be the E geometric isomer.138-140 Splitting (J = 8.3 Hz) is due to the two
equivalent protons at the C-3 and C-5 carbons. The singlet at 7.59 ppm, denoted as c,
represents the -hydrogen of the ,-unsaturated carbonyl unit. The doublet centered at
7.57 ppm, labeled as a, represents the two equivalent protons at the C-3 and C-5 carbons.
Splitting (J = 8.6 Hz) is due to the protons denoted as b. The splitting pattern for this
signal is slightly larger than expected; however, it is presumed that this is due to the
overlap between the two signals labeled as c and a.
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Figure 14: The 1H-NMR of Compound 87 in DMSO-d6
The doublet at 7.48 ppm, denoted as g, represents the hydrogen bonded to the C7’ carbon of the oxindole moiety. Splitting (J = 7.6 Hz) occurs due to the proton labeled
as f. As with the previous compound, a doublet of doublets would have been expected
due to meta-coupling with the proton at the C-5’ carbon (denoted as e); however, this
splitting is not observed. The triplet of doublets at 7.23 ppm, labeled as f, represents the
proton at the C-6’ carbon. Splitting (J = 1.1 Hz) occurs due to the proton denoted as d
and the two nonequivalent protons at e and g (J = 7.7 Hz). The doublet centered at 6.88
ppm, labeled as d, represents the proton on the C-4’ carbon. Splitting (J = 7.8 Hz) occurs
due to the proton denoted as e. A doublet of doublets should be expected with this signal
due to the meta-coupling between d and f, but this is not observed. The final peak in the
spectrum, a triplet of doublets labeled as e at 6.85 ppm, represents the proton at the C-5’
carbon. Splitting (J = 1.1 Hz) occurs due to the hydrogen denoted as g and the two
nonequivalent protons labeled as d and f (J = 7.6 Hz).
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3.4.2. 13C-NMR Spectrum
Thirteen signals are present in the 13C-NMR spectrum of compound 87 as shown
in Figure 15. The most downfield signal, labeled as m at 168.92 ppm, represents the
carbonyl carbon of the amide. The peak at 143.53 ppm, denoted as l, represents the C-7a’
carbon. The signal at 134.72 ppm, labeled as e, represents the -carbon in the ,unsaturated carbonyl unit. The next most downfield peak, labeled as a at 134.57 ppm,
represents the C-4 carbon. This experiences a significant downfield shift, as compared to
the 4-bromobenzaldehyde derivative, due to the more electronegative character of
chlorine. (According to the Pauling scale, chlorine possesses an electronegativity value of
3.16 as compared to 2.96 for bromine.144) The peak labeled as f at 133.80 ppm represents
the C-3’ carbon. The next most downfield peak, a singlet at 131.54 ppm labeled as c,
represents the two equivalent carbons at C-2 and C-6. The signal denoted as d at 130.82
ppm, represents the C-1 carbon. The singlet at 129.29 ppm, labeled as b, represents the
two equivalent carbons at the C-3 and C-5 carbons.

Figure 15: The 13C-NMR of Compound 87 in DMSO-d6
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The final five peaks represent the indolin-2-one. The signal, denoted as j at
128.66 ppm, represents the C-6’ carbon. The peak at 122.92 ppm, labeled as h, represents
the C-4’ carbon. The signal at 121.67 ppm, denoted as i, represents the C-5’ carbon. The
peak at 121.11 ppm, labeled as g, represents the C-3a’ carbon. The singlet at 110.67 ppm,
labeled as k, represents the C-7’ carbon.

3.5. Comparison of the 4-Bromo and 4-Chloro Spectra
3.5.1. 1H-NMR Spectra

As can be readily observed from Figure 16, the peaks representative of the
protons in the indolin-2-one (d, e, f, g, and h) remain conserved. Because these protons
are more than five carbons away from the electronegative atom, these hydrogens are
unaffected; therefore, no change in chemical shift is observed. The doublet that represents
the protons at the C-2 and C-6 carbons, labeled as b, remains unchanged between the two
spectra; however, the signal representative of the equivalent hydrogens at the C-3 and C5 carbons, denoted as a, is shifted upfield by 0.08 ppm in the 4-chloro derivative.
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Figure 16: Overlay of the 1H-NMR Spectra of Compound 86 (top) and Compound 87
(bottom) in DMSO-d6

3.5.2. 13C-NMR Spectra

The greatest difference in electronegativity effects can be observed in the overlay
of the 13C-NMR spectra of the 4-bromobenzaldehyde and 4-chlorobenzaldehyde
derivatives as shown in Figure 17. A substantial downfield shift (11.62 ppm) is observed
in the signal of 87, labeled as a, representing the carbon bonded to the chlorine. The only
other significant change is the slight upfield shift (2.94 ppm) noticed in the 13C-NMR of
compound 87. This peak, labeled as b, represents the C-3 and C-5 carbons. The other
signals remain relatively conserved.
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Figure 17: Overlay of the 13C-NMR Spectra for Compound 86 (top) and Compound 87
(bottom) in DMSO-d6

3.6. 4-Fluoro Moiety
3.6.1. 1H-NMR Spectrum

The last compound in this series is derived from 4-fluorobenzaldehyde (75). As
molecules that incorporate fluorine atoms present unique splitting patterns, these shall be
discussed here. In general, the presence of this element yields similar splitting patterns to
regular proton coupling; however, the range of splitting is farther for fluorines than
hydrogens. This is due to fluorine’s eight extra electrons.145 As all of the compounds
incorporating a fluorine atom in this thesis possess them on their aromatic rings, an
example of the effect of fluorine splitting on 4-bromofluorobenzene will be
evaluated.113,146 This molecule is provided in Figure 18 below.113,146
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Figure 18: 4-Bromofluorobenzene for 1H-NMR Explanation113,146
In this molecule, both the protons in the meta position (b) and the ortho position
(a) couple with the fluorine atom.113,146 Protons that are in closer proximity to the fluorine
element are split slightly more than those farther away; therefore, the protons at a possess
greater J values as compared to the protons at b. In general, 2JH-F values, determined for
ortho coupling, are approximately the same magnitude as the coupling constants observed
for two adjacent protons. This produces a signal that appears to be a triplet in the 1HNMR, but generally a slight difference between the magnitude of the ortho coupling
constants for the two adjacent protons as compared to the hydrogen and adjacent fluorine
is observed.146 This results in the presence of a doublet of doublets in the spectrum.146
The increased distance between the fluorine and protons present in the meta position
causes a decreased value in the observed coupling constant denoted as 3JH-F.146 The larger
difference in coupling constants in this instance allows for facile determination as a
doublet of doublets in the 1H-NMR.113 For this example, meta coupling observed in the
1

H-NMR has a 3JH-F value of 4.5 Hz; whereas the 2JH-F value is 8.5 Hz for the ortho

coupling.113,146
The 1H-NMR of compound 75 is provided in Figure 19. The most downfield
signal, denoted as h at 10.63 ppm, represents the proton of the hydrophilic N-H bond in
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the amide functional group. The next most downfield peak, a doublet of doublets
centered at 7.77 ppm and labeled as b, represents the two equivalent protons at C-2 and
C-6. Splitting (JH-H = 9.0 Hz) occurs due to the protons, labeled as a, at the C-3 and C-5
carbons and the 4-fluoro substituent (3JH-F = 5.6 Hz). As this signal is located within the
previously defined range,138-140 this molecule is determined to be the E isomer. The
singlet at 7.61 ppm, denoted as c, represents the vinyl proton. The next most downfield
signal, a doublet at 7.50 ppm labeled as g, represents the hydrogen at the C-7’ carbon.
This proton is split (J = 7.7 Hz) by the hydrogen denoted as f. Additional splitting, as
with the previously discussed molecules, would also be expected due to the proton at the
C-5’ carbon; however, a coupling constant between 1-3 Hz is not observed.

Figure 19: The 1H-NMR of Compound 75 in DMSO-d6
The doublet of doublets at 7.35 ppm, denoted as a, signifies the two equivalent
protons at the C-3 and C-5 carbons. Splitting (2JH-F = 8.9 Hz) is due to the fluorine
substituent at the C-4 carbon and the adjacent protons labeled as b (JH-H = 8.6 Hz). The
triplet of doublets at 7.23 ppm, denoted as f, signifies the proton at the C-6’ carbon. This
proton is split by the two nonequivalent hydrogens at e and g (J = 7.7 Hz) and the proton
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at d (J = 1.1 Hz). The apparent doublet at 6.88 ppm, denoted as d, represents the proton
at the C-4’ carbon. Splitting (J = 7.6 Hz) is due to the proton at e. The multiplicity for
this peak is irregular as compared to the expected doublet of doublet which should be
observed. Additional splitting should be present based upon the characteristic meta
coupling with the proton at f. The most upfield peak in the spectrum is a triplet of
doublets at 6.85 ppm and labeled as e. This peak represents the proton at the C-5’ carbon.
Splitting (J = 7.7 Hz) occurs due to the ortho coupling with the protons at d and f and the
meta coupling with g (J = 1.1 Hz).

3.6.2. 13C-NMR Spectrum
As with 1H-NMR, the presence of fluorine atoms in 13C-NMR spectra yields
unique multiplicities. The incorporation of this element into 13C-NMR causes splitting
patterns based on the formula 2𝑛𝐼 + 1.113,147 In this expression, 𝐼 stands for nuclear spin
and 𝑛 represents the number of nuclei.113,147 Due to fluorine’s ½ spin nucleus,145 the
number of observed peaks is one more than the number of fluorines. (For example, the
incorporation of one fluorine into a molecule would result in a doublet peak for those in
close enough proximity.) The magnitude of the J value, as observed in the 1H-NMR
spectrum, is dependent upon the distance each carbon is from the fluorine atom.146 The
largest coupling constants are observed when the carbon is directly attached to the
fluorine; whereas, smaller J values are present for those carbons farther away. Based
upon previous experience,113 the influence of these fluorine atoms generally has the
potential to affect up to five carbons.
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Figure 20: 4-Bromofluorobenzene for 13C-NMR Explanation113,146
Approximate coupling constants for para (4JC-F), meta (3JC-F), ortho (2JC-F), and
ipso (1JC-F) carbons can be determined through analysis of 4-bromofluorobenzene.113,146
This molecule is provided again in Figure 20.113,146 Using the 2𝑛𝐼 + 1 formula, where
the expression is equal to the observed multiplicity,147 it can be determined that each
carbon coupled with fluorine will present as a doublet in the 13C-NMR spectrum.113,146
The doublets observed for 4-bromofluorobenzene possess coupling constants of 3.3 Hz,
8.0 Hz, 22.8 Hz, and 246.6 Hz for the carbons in the para, meta, ortho, and ipso positions
respectively.113,146 Based on these approximations, the proper assignments for every
carbon in all subsequent 13C-NMR spectra of fluorinated compounds can be determined.
The 13C-NMR of compound 75 is provided in Figure 21. Four doublets (a-d) and
nine singlets (e-m) are observed. The most downfield singlet at 169.01 ppm, labeled as
m, represents the carbonyl carbon of the amide. The most downfield doublet, centered at
162.99 ppm and denoted as a, represents the C-4 carbon. Ipso splitting (1JC-F = 248.1 Hz)
occurs due to the 4-fluoro substituent. The next most downfield peak, a singlet at 143.43
ppm labeled as l, signifies the C-7a’ carbon. The singlet at 135.11 ppm, denoted as e,
represents the -carbon in the ,-unsaturated carbonyl. The doublet labeled as c at
132.17 ppm signifies the two equivalent carbons at C-2 and C-6. These carbons are split
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(3JC-F = 8.6 Hz) due to the meta coupling with the fluorine atom at C-4. The doublet
centered at 131.35 ppm, denoted as d, represents the C-1 carbon. Para splitting (4JC-F =
3.3 Hz) is observed due to the fluorine on the C-4 carbon.

Figure 21: The 13C-NMR of Compound 75 in DMSO-d6
The singlet at 130.65 ppm, labeled as f, represents the C-3’ carbon of the oxindole
moiety. The next most downfield signal, a singlet at 128.09 ppm and labeled as j,
represents the C-6’ carbon. The singlet at 122.75 ppm, denoted as h, represents the C-4’
carbon. The next most downfield peak, a singlet at 121.61 ppm and labeled as i, signifies
the C-5’ carbon. The singlet at 121.21 ppm, denoted as g, represents the C-3a’ carbon.
The most upfield doublet centered at 116.29 ppm, labeled as b, signifies the two
equivalent C-3 and C-5 carbons. Ortho coupling (2JC-F = 21.9 Hz) is observed due to the
fluorine atom at the C-4 carbon. The most upfield singlet, denoted as k at 110.63 ppm,
represents the C-7’ carbon of the oxindole motif.
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Figure 22: Overlay of the 13C-NMR Spectra of Compound 75 after 11 hr (top) and 1.5 hr
(bottom) in DMSO-d6
An additional piece of information to note is the tendency of benzylidene
oxindoles to isomerize in DMSO-d6 following prolonged periods of time. This issue is
not observed in the 1H-NMR spectra as these scans are completed fairly rapidly. The 13CNMR spectra, on the other hand, have the potential to possess extra peaks following
extended time (e.g. an overnight run.) As shown in Figure 22, by extending the period of
time in which the 13C-NMR spectrum for compound 75 was run, more than ten new
peaks appeared as opposed to when the molecule was analyzed for only 1.5 hrs.
Therefore, in order to accurately evaluate these BO derivatives, the 13C-NMRs should
ideally not be run for longer than one to two hours.

3.7. Comparison of the 4-Bromo, 4-Chloro, and 4-Fluoro Spectra
3.7.1. 1H-NMR Spectra
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The comparison of the 1H-NMRs of the 4-bromobenzaldehyde (86), 4chlorobenzaldehyde (87), and 4-fluorobenzaldehyde (75) derivatives are provided in
Figure 23. As in the previous comparison in Figure 16, the protons present on the
oxindole moiety (d-h) remain conserved as these protons are too far away to feel the
effects of the electronegative atoms. Thus, the only real differences in the 1H-NMRs of
these molecules are the signals representing the vinyl protons (c) and the protons derived
from the various benzaldehydes (denoted as a and b). The singlets representative of the
vinyl protons (c) shift downfield as the electronegative character of the halogens
increases.144 In compound 86, the peak is present at 7.56 ppm; whereas, molecules 87 and
75 possesses singlets at 7.59 ppm and 7.61 ppm respectively. Interestingly, a slight
downfield shift appears to be present (most substantially in the 4-fluoro derivative) for
the protons at C-2 and C-6 labeled as b. The signal representative of these protons is
shifted downfield 0.05 ppm in the 4-fluoro derivative as compared to the other two
compounds. Additionally, an upfield shift for the proton at a is observed in each
spectrum. As compared to the 4-bromo derivative, upfield shifts of 0.08 ppm and 0.30
ppm are observed in compounds 87 and 75 respectively. The difference between the
multiplicities observed is simply due to the fact that fluorine atoms cause additional
splitting;145-146 whereas, bromine and chlorine do not.
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Figure 23: Overlay of the 1H-NMR Spectra of Compound 86 (top), Compound 87
(middle), and Compound 75 (bottom) in DMSO-d6

3.7.2. 13C-NMR Spectra
An overlay of the 13C-NMR spectra for compounds 86, 87, and 75 is provided in
Figure 24. As expected, the majority of signals representing the carbons in the oxindole
moiety (f-m) remain conserved. The exception is the C-3’ carbon denoted as f. The signal
for this carbon experiences a significant upfield shift in the spectrum of compound 75;
however, the chemical shifts for f remain virtually the same in molecules 86 and 87. This
singlet is located at 134.16 ppm for compound 86; however, it is present at 133.80 ppm
for molecule 87 and 130.65 ppm for compound 75.
The most significant changes in the three spectra correspond to the carbons
derived from the benzaldehyde reagents as these are in close proximity to the
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electronegative atoms. The main downfield shifts due to electronegative character relates
to the carbons denoted as a. With respect to the 4-bromobenzaldehyde derivative, the
signals representing the carbons at C-4 are shifted downfield by 11.62 ppm and 40.04
ppm for the 4-chlorobenzaldehyde and 4-fluorobenzaldehyde derivatives respectively.
(As the order of electronegativity of these atoms from most electronegative to least is
fluorine, chlorine, and then bromine, it makes sense that the greatest downfield shift
would be caused by the fluorine atom and the most upfield shift would be observed in the
4-bromobenzaldehyde derivative.144)

Figure 24: Overlay of the 13C-NMR Spectra of Compound 86 (top), Compound 87
(middle), and Compound 75 (bottom) in DMSO-d6
Additionally, the signals representative of the C-3 and C-5 carbons, labeled as b,
experience a significant upfield shift as the electronegativity increases. In the 4bromobenzaldehyde derivative, the signal is present at 132.23 ppm; whereas, it is at
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129.29 ppm and 116.29 ppm for the 4-chlorobenzaldehyde and 4-fluorobenzaldehyde
derivatives respectively. This trend is also observed with the protons present on the C-3
and C-5 in the 1H-NMR as shown in Figure 16. The doublets are only observed in
compound 75 as the splitting patterns are unique for this molecule due to the
incorporation of the 4-fluoro motif.

3.8. 4-Hydroxyl Motif
3.8.1. 1H-NMR Spectra

As our research group was unable to incorporate the 4-hydroxyl motif into the
chalcone scaffold, and molecules possessing this moiety have been shown to exhibit
MAO-B inhibitory activity,87,100 a discussion of this structural unit seemed appropriate.
Generally, for alcohol moieties, the hydrogen of the hydroxyl group will not be split by
protons on the adjacent carbon in 1H-NMR; therefore, this peak will manifest as a
singlet.148 The chemical shift of an O-H peak can appear at various regions on the
spectrum depending on the surrounding environment.148
As an absolute determination of the chemical shift, deuterium oxide (D2O) can be
utilized. By this method, the hydroxyl peak disappears from the spectrum due to two
successive acid-base reactions: 1) the alcohol moiety (ROH) donates its proton to D2O to
yield +HOD2 and the alcohol anion (RO-) and 2) the positively charged oxygen species
donates a deuterium ion to reform the alcohol functional unit (ROD).148 As deuterium and
hydrogen atoms do not produce peaks in the same region of the 1H-NMR, the O-H bond
effectively disappears.148 This is shown for compound 95 in Figure 25. In this example,
there is an N-H bond due to the amide functional group of the benzylidene oxindole;
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therefore, this exchangeable proton is converted into a deuterium to form an N-D bond
that also disappears.149

Figure 25: Overlay of the 13C-NMR Spectra of Compound 95 with D2O (top) and
without D2O (bottom) in DMSO-d6
Additionally, as several of the synthesized compounds were derived from 5fluoroindolin-2-one, a molecule incorporating this structural unit was discussed. This
splitting is very similar to the discussion provided in the 4-fluoro moiety section;
however, as this reagent does not possess symmetrical protons, the signals are slightly
different. For this reason, a description of molecule 95 will be provided and then an
overlay with the starting material will be explained.
The 1H-NMR of compound 95 is provided in Figure 26. The most downfield
signal, a singlet at 10.56 ppm labeled as h, represents the proton in the N-H bond of the
amide functional group. The singlet at 10.23 ppm represents the proton of the hydroxyl
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unit. This signal, labeled as a, is barely visible in Figure 26 due to its small size and
rounded shape. Both the N-H and O-H signals are shifted downfield when DMSO-d6 is
used as the solvent.149 The singlet at 7.61 ppm, denoted as d, represents the vinyl proton.
The doublet centered at 7.61 ppm, labeled as c, represents the two equivalent protons at
the C-2 and C-6 carbons. Splitting (J = 8.4 Hz) occurs due to the protons denoted as b.
The splitting is slightly less than expected, as the coupling constant observed with b is
about J = 8.7 Hz, but this is likely due to the overlap between the two peaks at d and c.
Based on the chemical shift of these protons, the molecule can be assigned as the E
isomer.138-139 (Some ambiguity is present with this designation as the vinyl proton has a
chemical shift closer to the Z isomer; however, it is stated that the assignment of the
geometric isomer is done by the vinyl proton when both the C-2 and C-6 carbons are
substituted.138,140 They are not in this case.)

Figure 26: The 1H-NMR of Compound 95 in DMSO-d6

The doublet of doublets centered at 7.39 ppm, labeled as e, represents the proton
at the C-4’ carbon. Splitting (J = 2.5 Hz) occurs due to the proton at f and the fluorine
atom bonded to the carbon at the C-5’ position (2JH-F = 9.5 Hz). The doublet of doublets
of doublets centered at 7.05 ppm, denoted as f, represents the proton at the C-6’ carbon.
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Splitting (J = 8.6 Hz) occurs due to the proton at g, the fluorine substituent at C-5’ (2JH-F
= 9.2 Hz), and the proton at e (J = 2.6 Hz). Based on previous experience with fluorine
atoms in 1H-NMR,113 I would have expected a slight difference in the coupling constant
for 2JH-F. Generally, based on previously analyzed 1H-NMR spectra,113 the J value should
be around 9.5 Hz as observed in the splitting pattern for the proton labeled as e.

The doublet centered at 6.93 ppm, denoted as b, represents the two chemically
equivalent protons at the C-3 and C-5 carbons. Splitting (J = 8.7 Hz) occurs due to the
protons labeled as c. The most upfield peak in the spectrum, a doublet of doublets
denoted as g at 6.85 ppm, represents the proton at the C-7’ carbon of the oxindole moiety.
Splitting (3JH-F = 4.7 Hz) occurs due to the fluorine substituent at the C-5’ carbon and the
proton at f (J = 8.6 Hz).

Figure 27: Overlay of the 1H-NMR Spectra of the 5-Fluoroindolin-2-one Reagent (top)
and Compound 95 in DMSO-d6
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The overlay of the 1H-NMRs of the 5-fluoroindolin-2-one reagent and compound
95 is provided in Figure 27. The amide N-H bond remains moderately conserved;
however, a downfield shift (0.19 ppm) is observed in the product. The peaks closest to
the fluorine atoms (denoted as e and f) are split the most as they are nearest to the
electronegative element. The proton labeled as e at the C-4’ carbon appears as a doublet
of doublets in both spectra. This is observed due to two distinct coupling constants. The
larger magnitude J value is due to ortho coupling with the fluorine substituent on the C-5’
carbon and a smaller value is from meta coupling with the proton at f. The multiplicity
observed for the proton at f appears to resemble a doublet of doublets of doublets in both
spectra. Interestingly, the 2JH-F value is approximately 9.8 Hz in the reagent; whereas, the
2J

H-F

value is 9.2 Hz for the product. This slight difference (0.5 Hz) may be attributed to

the lack of resolution of each peak in the doublet of doublets of doublets in the product
spectrum. Splitting due to the protons at g (J = 8.6 Hz) and e (J = 2.7 Hz) is conserved.
The final signal, labeled as g and representing the proton at the C-7’ carbon, is
virtually exactly the same. Closer inspection shows additional splitting (J = 0.3 Hz) on
the reagent spectra for this peak, likely due to para coupling with the proton at e, but this
is not observed in the product. The main difference in the aliphatic region of these two
spectra relates to the location of d. In the reagent, this proton is present on the C-3’
carbon and, due to the lack of aromaticity, appears as a singlet in the aliphatic region at
3.49 ppm with an integration of two. As no free protons are present on the C-3’a carbon
in the product, no aliphatic hydrogens are present in the 1H-NMR spectrum for compound
95. Instead, the proton labeled as d in the product is the -hydrogen in the ,unsaturated carbonyl. Because this is a conjugated vinyl proton, it is located in the

84

aromatic region. The remaining peaks are solely present in the product spectrum as they
are hydrogens derived from the 4-hydroxybenzaldehyde reagent.

3.8.2. 13C-NMR Spectra
As expected, thirteen unique signals are present in the 13C-NMR of compound 95
as shown in Figure 28. Six of these peaks are singlets (a, b, c, d, e, and m) and seven are
doublets (f-l). The most downfield singlet, labeled as m and present at 169.48 ppm,
represents the carbonyl carbon of the amide functional group. This peak falls within the
representative 160-180 ppm range for carbons of amide functional groups.141 The next
most downfield signal at 160.11 ppm, a singlet denoted as a, represents the C-4 carbon of
the 4-hydroxybenzaldehyde reagent. This peak experiences a downfield shift due to the
proximity of the electronegative oxygen atom. The doublet centered at 157.61 ppm,
labeled as i, represents the C-5’ carbon. Ipso splitting (1JC-F = 234.6 Hz) occurs due to the
fluorine substituent. This signal also experiences a significant downfield shift as fluorine
is the most electronegative element.144
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Figure 28: The 13C-NMR of Compound 95 in DMSO-d6
The doublet centered at 139.24 ppm, denoted as l, represents the C-7a’ carbon
derived from the 5’-fluorooxindole reagent. Para splitting (4JC-F = 1.3 Hz) occurs due to
the fluorine substituent on the C-5’ carbon. The singlet at 138.73 ppm, denoted as e,
represents the -carbon in the ,-unsaturated carbonyl. The next most downfield singlet,
labeled as c at 132.40 ppm, represents the two equivalent carbons at C-2 and C-6. The
signal at 125.08 ppm, denoted as d, represents the C-1 carbon. The doublet centered at
124.83 ppm, labeled as f, represents the C-3’ carbon derived from the 5’-fluoroindolin-2one reagent. Para coupling (4JC-F = 2.9 Hz) occurs due to the interaction of this carbon
with the 5’-fluoro substituent. The next most downfield doublet, denoted as g at 122.75
ppm, represents the C-3a’ carbon. Meta coupling (3JC-F = 9.0 Hz) occurs due to the 5’fluoro substituent on the 5’-fluorooxindole moiety. The most upfield singlet, labeled as b
at 116.23 ppm, represents the two equivalent carbons at C-3 and C-5.
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The final three signals present in this spectrum are doublets and represent peaks
derived from the 5’-fluorooxindole reagent. Each of these signals is split into a doublet
by the 5’-fluoro substituent. The most downfield doublet, labeled as j at 116.03 ppm,
represents the C-6’ carbon. Ortho coupling (2JC-F = 23.7 Hz) is observed. The doublet
centered at 110.96 ppm, denoted as k, represents the C-7’ carbon. Meta coupling (3JC-F =
8.4 Hz) is observed. The most upfield doublet, centered at 109.44 ppm and labeled as h,
represents the C-4’ carbon. Ortho coupling (2JC-F = 25.9 Hz) is observed.
One of the more interesting things to note regarding the 5’-fluorooxindole moiety
is how far the influence of fluorine is felt in terms of splitting. It is expected that the
molecule would have the potential to cause splitting up to four carbons away (at the para
position); however, one might not expect the fluorine to split every carbon in the
structure except for the carbonyl carbon (C-2’). An overlay of the 13C-NMR spectra of
the 5’-fluoroindolin-2-one reagent and compound 95 is provided in Figure 29. The
spectrum for the 5’-fluorooxindole starting material illustrates that the para coupling at C3’ remains conserved in compound 95. A comparison of these two 13C-NMR spectra also
allows for the proper designations of the newly formed carbons following the
condensation reaction.
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Figure 29: Overlay of the 13C-NMR Spectra of the 5’-Fluoroindolin-2-one Reagent (top)
and Compound 95 (bottom) in DMSO-d6
Upon analysis of these two spectra, it can be determined that many of the peaks
remain relatively conserved between the reagent and the desired product. (As this starting
material is still primarily unchanged in the product, these peaks should be virtually the
same.) One of the main differences between the two spectra is the position of the C-3’
carbon denoted as f. In the reagent, this peak represents an unconjugated aliphatic carbon
and is therefore present at 36.64 ppm. Splitting (4JC-F = 1.7 Hz) occurs due to the 5’fluoro substituent on the C-5’ carbon. In the product, this carbon is included in the
conjugated system between the two aromatic rings; therefore, its chemical shift is 124.83
ppm. It also experiences splitting (4JC-F = 2.9 Hz) due to the 5’-fluoro motif.

Additionally, the carbonyl carbon of the amide functional group experiences a
significant upfield shift (7.14 ppm) in the product due to the introduction of a more
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highly conjugated system. As the original carbonyl carbon is not conjugated, this peak is
shifted farther downfield. Lastly, the carbons designated as k and h are reversed in the
product as compared to the reagent. This determination is made due to coupling constants
calculated from these doublets. The J value of h should be approximately 25 Hz due to
ortho coupling; whereas, the J value of k should be about 8-10 Hz due to meta
coupling.136
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4. Conclusion
A library of benzylidene oxindoles was synthesized to act as potential MAO-B
inhibitors in order to alleviate some of the symptoms of Parkinson’s disease when used
simultaneously with L-dopa. These BO compounds, as compared to derivatives of the
previously analyzed chalcone scaffold,97-100,109-110 have not been evaluated for their
ability to inhibit this isozyme. As fourteen of the molecules described herein have not
been reported in literature previously, these novel compounds provide a possible new
scaffold for the determination of a lead molecule against MAO-B. Based on biological
results from the compounds in this study, the structural moieties that yielded optimized
activity could be ascertained and incorporated into future libraries. Additionally, as these
molecules require only a one-step synthesis, they provide a simplistic and economical
molecular skeleton that affords simply altering the structural groups on the benzaldehyde
reagents in order to change the functionalization of each compound.
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5. Future work
In order to assess the potential of these molecules to act as MAO-B inhibitors,
these compounds must be evaluated in biological screenings. Unfortunately, this step
could not be completed as our chalcone molecules are currently still being screened. In
order to respect our collaborator’s time, we were more focused on finishing one entire
project rather than provide them with multiple scaffolds simultaneously.
The second critically important step in future work would be to separate these
molecules into their respective E and Z isomers. As stated previously, the actual potency
of these BO derivatives cannot be determined without fully isolating the geometric
isomers. In this manner, the true selectivity and IC50 value of each compound could be
assessed and a lead molecule could be found. Subsequently, these compounds could then
be optimized into future MAOIs. This must also be completed because, as previously
stated, one of the stereoisomers may be actually responsible for the observed biological
activity, while the other may potentially cause deleterious health effects. In this study,
only one molecule falls into this category. However, as BO derivatives have a propensity
to exist as both E and Z isomers, this is a critical step for future analyses performed using
this scaffold.
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6. Experimental
6.1. Chemical Analysis113,138
Melting point (mp), thin layer chromatography (TLC), gas chromatography-mass
spectrometry (GC/MS), and nuclear magnetic resonance (NMR) were the main chemical
and instrumental analyses performed in this investigation. Melting point analysis was
performed using an Electrothermal melting point apparatus with open capillary tubes.
TLC was performed using silica gel plates with the reported solvent systems. The GC
was coupled with a mass spectrometer with a Hewlett-Packard 5973 mass selective
detector/quadrupole system. The GC/MS data was collected from a Hewlett-Packard
6890 Series FC with auto injection. The determined mass fragments were reported as
mass per charge or m/z. The 1H-NMR and 13C-NMR data was collected using CDCl3 or
DMSO-d6 solutions in a Bruker Avance 300 MHz NMR. Chemical shifts for 1H-NMR
are provided in δ (ppm) downfield from the internal standard tetramethylsilane. The
coupling constants (J values) are provided in Hz, where appropriate, for both 1H-NMR
and 13C-NMR. The multiplicities are described using the following abbreviations: singlet,
s; doublet, d; doublet of doublets, dd; doublet of doublets of doublets, ddd; triplet, t;
triplet of doublets, td; quartet, q; quintet, quint; multiplet, m.
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6.2. Indolin-2-one Derivatives
3-(4-methoxybenzylidene)-indolin-2-one <TK-8-77> (66)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8552 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-methoxybenzaldehyde (0.9400 mL, 7.706 mmol, 1.2 equiv.)
was added and stirred at 90 °C for 15 min. Piperidine (0.1000 mL, 0.944 mmol, 0.147
equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for 3 h
while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow precipitate (1.2959 g, 80.3 %) was collected by vacuum
filtration: mp 156-157 °C (lit. mp128 158-159 °C); Rf 0.55 (50:50 EtOAc/Hexane);
GC/MS at 100.0 % pure (M+ 251.2); 1H-NMR (DMSO-d6, 300 MHz) δ: 3.83 (s, 3H, OCH3), 6.86 (m, 2H, Ar-H), 7.07 (d, J = 8.8 Hz, 2H, Ar-H), 7.21 (td, J = 1.1 Hz, J = 7.7
Hz, 1H, Ar-H), 7.59 (s, 1H, vinyl-H), 7.66 (d, J = 7.6 Hz, 1H, Ar-H), 7.70 (d, J = 8.4 Hz,
2H, Ar-H), 10.57 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 55.82, 110.48,
114.71, 121.48, 121.62, 122.51, 126.05, 126.07, 127.06, 130.13, 131.95, 136.44, 143.12,
160.98, 169.35 ppm.

3-(2-methoxybenzylidene)-indolin-2-one <TK-7-195 T> (67)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8551 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 2-methoxybenzaldehyde (1.0490 g, 7.706 mmol, 1.200 equiv.)
was added and stirred at 90 °C for 22 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147
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equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for 3 h
while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow precipitate (1.4917 g, 92.4 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.2900 g) as a yellow solid: mp 215-217 °C (lit. mp128 221-222 °C); Rf 0.64 (50:50
EtOAc/Hexane); GC/MS at 100.0 % pure (M+ 251.2); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.86 (s, 3H, -OCH3), 6.84 (m, 2H, Ar-H), 7.08 (apparent t, J = 7.5 Hz, 1H, Ar-H), 7.16
(dd, J = 0.7 Hz, J = 8.4 Hz, 1H, Ar-H), 7.21 (td, J = 1.2 Hz, J = 7.6 Hz, 1H, Ar-H), 7.41
(d, J = 7.7 Hz, 1H, Ar-H), 7.49 (apparent t, J = 7.9 Hz, 1H, Ar-H), 7.65 (s, 1H, vinyl-H),
7.68 (dd, J = 1.7 Hz, J = 7.7 Hz, 1H, Ar-H), 10.59 (s, 1H, N-H); 13C-NMR (DMSO-d6,
300 MHz) δ: 56.06, 110.49, 112.02, 120.68, 121.50, 121.52, 122.71, 123.26, 127.76,
129.96, 130.37, 132.19, 143.19, 158.07, 169.04 ppm.

3-(3,4-dimethoxybenzylidene)-indolin-2-one <TK-8-29 T> (68)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8553 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 3,4-dimethoxybenzaldehyde (1.2802 g, 7.706 mmol, 1.200
equiv.) was added and stirred at 90 °C for 17 min. Piperidine (0.0934 mL, 0.944 mmol,
0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for
3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow-orange precipitate (1.8425 g, 102.0 %) was collected by vacuum
filtration. The sample was then triturated with EtOH to yield the pure product (0.2088 g)
as a yellow solid: mp 237-244 °C (lit. mp129 239-242 °C); Rf 0.65 (50:50
EtOAc/Hexane); GC/MS at 95.9 % pure (M+ 281.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
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3.84 (s, 3H, -OCH3), 3.84 (s, 3H, -OCH3), 6.84 (d, J = 7.5 Hz, 1H, Ar-H), 6.98 (td, J =
1.0 Hz, J = 7.6 Hz, 1H, Ar-H), 7.07 (d, J = 8.6 Hz, 1H, Ar-H), 7.18 (td, J = 1.1 Hz, J =
7.6 Hz, 1H, Ar-H), 7.67 (d, J = 7.4 Hz, 1H, Ar-H), 7.75 (s, 1H, vinyl-H), 7.84 (dd, J = 2.0
Hz, J = 8.8 Hz, 1H, Ar-H), 8.70 (d, J = 2.0 Hz, 1H, Ar-H), 10.57 (s, 1H, N-H); 13C-NMR
(DMSO-d6, 300 MHz) δ: 55.87, 56.02, 109.66, 111.55, 115.46, 119.60, 121.35, 124.40,
125.90, 127.71, 127.87, 128.60, 137.85, 140.65, 148.44, 151.57, 167.91 ppm.

3-(2,5-dimethoxybenzylidene)-indolin-2-one <TK-8-109 R> (69)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8552 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 2,5-dimethoxybenzaldehyde (1.2807 g, 7.706 mmol, 1.200
equiv.) was added and stirred at 90 °C for 5 min. Piperidine (0.0934 mL, 0.944 mmol,
0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for
3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow-orange precipitate (1.6296 g, 90.2 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.2960 g) as orange crystals: mp 197-198 °C (lit. mp128 189-192 °C); Rf 0.27, 0.47
(30:70 EtOAc/Hexane); GC/MS at 100.0 % pure (M+ 281.1); 1H-NMR (DMSO-d6, 300
MHz) δ: 3.73 (s, 3H, -OCH3), 3.80 (s, 3H, -OCH3), 6.86 (m, 2H, Ar-H), 7.06 (m, 2H, ArH), 7.22 (m, 2H, Ar-H), 7.46 (d, J = 7.7 Hz, 1H, Ar-H), 7.62 (s, 1H, vinyl-H), 10.60 (s,
1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 56.01, 56.42, 110.54, 113.15, 114.85,
117.38, 121.47, 121.51, 122.89, 123.82, 127.97, 130.42, 131.86, 143.29, 152.31, 153.03,
169.03 ppm.
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3-(3,4,5-Trimethoxybenzylidene)-indolin-2-one <TK-7-1 T> (70)
To a 2 Dram vial was added indolin-2-one (0.8547 g, 6.422 mmol) with 3,4,5trimethoxybenzaldehyde (1.5122 g, 7.706 mmol, 1.200 equiv.), piperidine (0.0934 mL,
0.944 mmol, 0.147 equiv.), EtOH (4 mL), and a stir bar. The vial was placed on a hot
plate at 90 °C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath
to induce crystallization. A yellow precipitate (1.6088 g, 80.5 %) was collected by
vacuum filtration. The sample was then triturated with MeOH to yield the pure product
(1.5032 g) as a yellow solid: mp 196-198 °C (lit. mp130 189-191 °C); Rf 0.58 (50:50
EtOAc/Hexane); GC/MS at 92.7 % pure (M+ 311.2); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.75 (s, 3H, -OCH3), 3.85 (s, 6H, -OCH3), 6.85 (d, J = 7.5 Hz, 1H, Ar-H), 7.00 (td, J =
1.0 Hz, J = 7.6 Hz, 1H, Ar-H), 7.21 (td, J = 1.1 Hz, J = 7.6 Hz, 1H, Ar-H); 7.68 (d, J =
7.5 Hz, 1H, Ar-H), 7.70 (s, 1H, vinyl-H), 8.03 (s, 2H, Ar-H), 10.60 (s, 1H, N-H); 13CNMR (DMSO-d6, 300 MHz) δ: 56.35, 109.79, 110.61, 119.84, 121.48, 125.65, 126.04,
129.07, 130.00, 137.77, 140.22, 140.90, 152.70, 167.73 ppm.

3-(2,4,6-Trimethoxybenzylidene)-indolin-2-one <TK-13-81 R> (71)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8552 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 2,4,6-trimethoxybenzaldehyde (1.2598 g, 6.422 mmol, 1.000
equiv.) was added and stirred at 90 °C for 7 min. Piperidine (0.0934 mL, 0.944 mmol,
0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for
3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow precipitate (1.6957 g, 84.8 %) was collected by vacuum
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filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.2025 g) as a yellow solid: mp 193-194 °C (lit. mp131 188 °C); Rf 0.46, 0.56 (50:50
EtOAc/Hexane); GC/MS at 98.8 % pure (M+ 311.2); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.75 (s, 6H, -OCH3), 3.87 (s, 3H, -OCH3), 6.36 (s, 2H, Ar-H), 6.82 (m, 3H, Ar-H), 7.14
(ddd, J = 2.2 Hz, J = 6.3 Hz, J = 8.9 Hz, 1H, Ar-H), 7.40 (s, 1H, vinyl-H), 10.43 (s, 1H,
N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 55.96, 56.07, 91.22, 105.16, 109.72, 121.27,
122.92, 124.21, 127.55, 127.91, 129.15, 142.15, 159.49, 163.22, 169.44 ppm.

3-(4-hydroxy-3-methoxybenzylidene)-indolin-2-one <TK-7-131 T> (72)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8551 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-hydroxy-3-methoxybenzaldehyde (1.1725 g, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 7 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow precipitate (1.4313 g, 83.4 %) was collected by vacuum
filtration. The sample was then triturated with EtOH to yield the pure product (0.2232 g)
as a yellow solid: mp 220-222 °C (lit. mp132 226-227 °C); Rf 0.52 (50:50
EtOAc/Hexane); GC/MS at 100.0 % pure (M+ 267.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.86 (s, 3H, -OCH3), 6.83 (d, J = 7.5 Hz, 1H, Ar-H), 6.87 (d, J = 8.3 Hz, 1H, Ar-H), 6.97
(td, J = 1.0 Hz, J = 7.6 Hz, 1H, Ar-H), 7.17 (td, J = 1.1 Hz, J = 7.6 Hz, 1H, Ar-H), 7.65
(d, J = 7.4 Hz, 1H, Ar-H), 7.70 (s, 1H, vinyl-H), 7.75 (dd, J = 2.0 Hz, J = 8.6 Hz, 1H, ArH); 8.70 (d, J = 2.0 Hz, 1H, Ar-H), 9.87 (s, 1H, O-H), 10.54 (s, 1H, N-H); 13C-NMR
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(DMSO-d6, 300 MHz) δ: 55.96, 109.58, 115.61, 116.61, 119.38, 121.27, 123.35, 126.08,
126.58, 128.29, 128.38, 138.31, 140.44, 147.44, 150.20, 151.50, 167.96 ppm.

3-(3-hydroxy-4-methoxybenzylidene)-indolin-2-one <TK-7-143 R> (73)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8549 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 3-hydroxy-4-methoxybenzaldehyde (1.1725 g, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 8 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. To ensure maximum crystallization, the sample was placed into the fridge
overnight. A yellow-orange precipitate (1.0624 g, 61.9 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.1499 g) as a yellow solid: mp 164-165 °C (lit. mp128 173-176 °C); Rf 0.48 (50:50
EtOAc/Hexane); GC/MS at 100.0 % pure (M+ 267.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.85 (s, 3H, -OCH3), 6.89 (m, 2H, Ar-H), 7.06 (d, J = 8.1 Hz, 1H, Ar-H), 7.21 (m, 3H,
Ar-H), 7.50 (s, 1H, vinyl-H), 7.74 (d, J = 7.8 Hz, 1H, Ar-H), 9.41 (s, 1H, O-H), 10.55 (s,
1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 56.09, 99.98, 110.42, 112.52, 116.66,
121.44, 121.63, 122.65, 122.79, 125.73, 127.32, 130.03, 136.92, 143.06, 146.89, 149.88,
169.44 ppm.

3-(4-hydroxybenzylidene)-indolin-2-one <TK-8-89 R> (74)
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To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8550 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-hydroxybenzaldehyde (0.9413 g, 7.706 mmol, 1.200 equiv.)
was added and stirred at 90 °C for 32 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147
equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for 12
min while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A bright yellow precipitate (1.3180 g, 86.5 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.2154 g) as a yellow solid: mp: >250 °C (lit. mp133 255 °C); Rf 0.65 (50:50
EtOAc/Hexane); GC/MS at 96.3 % pure (M+ 237.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
6.88 (m, 2H, Ar-H), 6.91 (d, J = 8.6 Hz, 2H, Ar-H), 7.21 (td, J = 1.0 Hz, J = 7.7 Hz, 1H,
Ar-H), 7.54 (s, 1H, vinyl-H), 7.62 (d, J = 8.3 Hz, 2H, Ar-H), 7.70 (d, J = 7.7 Hz, 1H, ArH), 10.15 (s, 1H, O-H), 10.53 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 110.39,
116.09, 121.46, 121.77, 122.49, 125.11, 125.46, 129.85, 132.28, 137.05, 142.94, 159.76,
169.51 ppm.

3-(4-fluorobenzylidene)indolin-2-one <CF-2-8> (75)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8617 g, 6.472 mmol) and a
stir bar were added. The vial was was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 4-fluorobenzaldehyde (0.8300 mL, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 5 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 1.5 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
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crystallization. A yellow precipitate (1.2690 g, 82.7 %) was collected by vacuum
filtration: mp 186-188 °C (lit. mp129 194-196 °C); Rf 0.53 (50:50 EtOAc/Hexane); GCMS
at 100.0 % pure (M+ 239.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 6.85 (td, J = 1.1 Hz, J =
7.7 Hz, 1H, Ar-H), 6.88 (apparent d, J = 7.6 Hz, 1H, Ar-H), 7.23 (td, J = 1.1 Hz, J = 7.7
Hz), 7.35 (dd, JH-H = 8.6 Hz, 2JH-F = 8.9 Hz, 2H, Ar-H), 7.50 (d, J = 7.7 Hz, 1H, Ar-H),
7.61 (s, 1H, vinyl-H), 7.77 (dd, 3JH-F = 5.6 Hz, JH-H = 9.0 Hz, 2H, Ar-H), 10.63 (s, 1H, NH); 13C-NMR (DMSO-d6, 300 MHz) δ: 110.63, 116.29 (d, 2JC-F = 21.9 Hz), 121.21,
121.61, 122.75, 128.09, 130.65, 131.35 (d, 4JC-F = 3.3 Hz), 132.17 (d, 3JC-F = 8.6 Hz),
135.11, 143.43, 162.99 (d, 1JC-F = 248.1 Hz), 169.01 ppm.

3-(2-fluorobenzylidene)indolin-2-one <TK-7-187 R> (76)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.855 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 2-fluorobenzaldehyde (0.8120 mL, 7.706 mmol, 1.200 equiv.)
was added and stirred at 90 °C for 15 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147
equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for 3 h
while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow precipitate (1.2709 g, 82.7 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.1826 g) as a yellow solid: mp 223-225 °C (lit. mp128 218-220 °C); Rf 0.77 (50:50
EtOAc/Hexane); GC-MS at 100.0 % pure (M+ 239.1); 1H-NMR (CDCl3, 300.13 MHz): δ
6.81 (m, 2H, Ar-H), 7.14 (m, 3H, Ar-H), 7.37 (m, 2H, Ar-H), 7.64 (t, J = 7.5 Hz, 1H, ArH), 7.74 (s, 1H, vinyl-H), 7.83 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 110.66,
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116.49 (d, 2JC-F = 21.2 Hz), 121.10, 121.75, 122.76 (d, 2JC-F = 14.5 Hz), 123.12 (d, 4JC-F =
1.4 Hz), 125.17 (d, 3JC-F = 3.4 Hz), 127.84 (d, 3JC-F = 2.8 Hz), 130.30, 130.93 (d, 4JC-F =
2.5 Hz), 131.02, 132.40 (d, 3JC-F = 8.3 Hz), 143.58, 160.11 (d, 1JC-F = 248.6 Hz), 168.55
ppm.

3-(2,6-difluorobenzylidene)indolin-2-one <MVP-1-5> (77)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8560 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 2,6-difluorobenzaldehyde (0.8300 mL, 7.706 mmol, 1.200
equiv.) was added and stirred at 90 °C for 20 min. Piperidine (0.0934 mL, 0.944 mmol,
0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for
3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow-orange precipitate (1.4552 g, 88.1 %) was collected by vacuum
filtration: mp 222-225 °C (no lit. mp); Rf 0.76 (50:50 EtOAc/Hexane); GC-MS at 100.0
% pure (M+ 257.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 6.87 (m, 3H, Ar-H), 7.29 (m, 4H,
Ar-H), 7.61 (apparent quint, J = 7.1 Hz, 1H, Ar-H), 10.73 (s, 1H, N-H); 13C-NMR
(DMSO-d6, 300 MHz) δ: 110.62, 112.23, 112.62 (dd, 4JC-F = 1.9 Hz, 2JC-F = 22.3 Hz),
112.54, 112.69, 120.24 (t,4JC-F = 2.0 Hz), 121.16, 121.98, 123.58 (t, 3JC-F = 2.2 Hz),
131.32, 132.47 (t, 2JC-F = 10.4 Hz), 132.76, 143.70, 160.09 (dd, 3JC-F = 7.1 Hz, 1JC-F =
249.9 Hz), 168.01 ppm.

3-(4-(trifluoromethyl)benzylidene)indolin-2-one <TK-7-163 R> (78)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.855 g, 6.422 mmol) and a
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stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-(trifluoromethyl)benzaldehyde (0.8554 mL, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 15 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. An orange precipitate (1.4220 g, 76.5 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.1083 g) as an orange solid: mp 228-231 °C (lit. mp128 186-189 °C); Rf 0.83 (50:50
EtOAc/Hexane); GC-MS at 100.0 % pure (M+ 289.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
6.83 (dd, J = 0.9 Hz, J = 7.6 Hz, 1H, Ar-H), 7.00 (td, J = 1.0 Hz, J = 7.6 Hz, 1H, Ar-H),
7.25 (td, J = 1.1 Hz, J = 7.6 Hz, 1H, Ar-H), 7.73 (apparent d, J = 7.6 Hz, 1H, Ar-H), 7.80
(d, J = 8.1 Hz, 2H, Ar-H), 7.88 (s, 1H, vinyl-H), 8.46 (d, J = 8.6 Hz, 2H, Ar-H), 10.70 (s,
1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 110.00, 120.82, 121.69, 122.75, 124.79,
125.30 (q, 2JC-F = 3.7 Hz), 126.36, 129.90 (q, 1JC-F = 31.6 Hz), 129.58, 130.20, 130.34,
132.43, 134.79, 138.17, 141.75, 143.76, 167.29 ppm.

3-(2-(trifluoromethyl)benzylidene)indolin-2-one <TK-7-171> (79)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.855 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 2-(trifluoromethyl)benzaldehyde (1.015 mL, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 15 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
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crystallization. A yellow precipitate (1.4021 g, 75.5 %) was collected by vacuum
filtration: mp 165-167 °C (lit. mp128 175-177 °C); Rf 0.53 (30:70 EtOAc/Hexane); GCMS at 100.0 % pure (M+ 289.1), 1H-NMR (CDCl3, 300 MHz) δ: 6.80 (td, J = 1.0 Hz, J =
7.6 Hz, 1H, Ar-H), 6.99 (t, J = 8.2 Hz, 2H, Ar-H), 7.23 (td, J = 1.2 Hz, J = 7.7 Hz, 1H,
Ar-H), 7.58 (t, J = 7.5 Hz, 1H, Ar-H), 7.65 (t, J = 7.3 Hz, 1H, Ar-H), 7.75 (d, J = 7.6 Hz,
1H, Ar-H), 7.84 (d, J = 7.6 Hz, 1H, Ar-H), 8.00 (d, J = 2.3 Hz, 1H, vinyl-H), 9.73 (s, 1H,
N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 110.78, 120.88, 121.75, 122.61, 123.07,
126.86 (q, 1JC-F = 5.2 Hz), 127.24, 127.64, 130.17, 130.73, 130.84, 131.12, 131.33,
133.39, 133.71 (q, 2JC-F = 1.9 Hz), 143.67, 151.51, 168.29 ppm.

3-(4-Nitrobenzylidene)indolin-2-one <MVP-1-67 T> (80)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.855 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90°C until full dissolution.
Following full dissolution, 4-nitrobenzaldehyde (1.1645g, 7.706 mmol, 1.200 equiv.) was
added and stirred at 90 °C for 15 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147 equiv.)
was then added dropwise and the vial was placed on a hot plate at 90°C for 3 h while
stirring. The vial was cooled to rt and placed into an ice bath to induce crystallization. An
orange precipitate (1.5799 g, 92.6 %) was collected by vacuum filtration. The product
was then triturated with EtOH to yield the pure product (0.1267 g) as a bright orange
solid: mp 245-247 °C (lit. mp134 224-225 °C); Rf 0.38 (30:70 EtOAc/Hexane); GC-MS at
100.0 % pure (M+ 266.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 6.85 (td, J = 1.1 Hz, J = 7.7
Hz, 1H, Ar-H), 6.89 (apparent d, J = 8.4 Hz, 1H, Ar-H), 7.26 (td, J = 1.0 Hz, J = 7.7 Hz,
1H, Ar-H), 7.40 (apparent d, J = 7.7 Hz, 1H, Ar-H), 7.67 (s, 1H, vinyl-H), 7.95 (d, J =

103

9.0 Hz, 2H, Ar-H), 8.35 (d, J = 8.6 Hz, 2H, Ar-H), 10.71 (s, 1H, N-H); 13C-NMR
(DMSO-d6, 300 MHz) δ: 110.81, 120.70, 121.76, 123.28, 124.28, 130.50, 130.84,
131.41, 133.26, 141.86, 143.94, 147.82, 168.60 ppm.

3-(2-Nitrobenzylidene)indolin-2-one <TK-8-21 R> (81)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8554 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-nitrobenzaldehyde (1.1648 g, 7.706 mmol, 1.200 equiv.)
was added and stirred at 90 °C for 15 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147
equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for 3 h
while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. An orange precipitate (0.4555 g, 26.6 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.1528 g) as an orange solid: mp 234-239 °C (lit. mp132 234-235 °C); Rf 0.70 (50:50
EtOAc/Hexane); GC-MS at 91.0 % pure (M+ 266.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
6.74 (td, J = 0.8 Hz, J = 7.5 Hz, 1H, Ar-H), 6.81 (d, J = 7.0 Hz, 1H, Ar-H), 6.87 (d, J =
7.7 Hz, 1H, Ar-H), 7.20 (td, J = 1.3 Hz, J = 7.6 Hz, 1H, Ar-H), 7.83 (m, 4H, Ar-H), 8.31
(dd, J = 0.9 Hz, J = 8.1 Hz, 1H, Ar-H), 10.69 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300
MHz) δ: 110.72, 121.00, 121.66, 122.85, 125.85, 129.04, 130.88, 131.05, 131.11, 131.43,
132.87, 134.93, 143.50, 147.54, 168.42 ppm.

3-(4-(dimethylamino)benzylidene)indolin-2-one <TK-7-61 T> (82)
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To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8550 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-(dimethylamino)benzaldehyde (1.1496 g, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 15 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A red crystalline precipitate (1.5404 g, 90.7 %) was collected by vacuum
filtration. The sample was then triturated with EtOH to yield the pure product (0.1422 g)
as a red solid: mp 225-226 °C (lit. mp134 225-232 °C); Rf 0.58, 0.71 (50:50
EtOAc/Hexane); GC-MS at 100.0 % pure (M+ 264.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.03 (s, 6H, dimethylamino-H), 6.76 (d, J = 9.2 Hz, 2H, Ar-H), 6.80 (d, J = 7.5 Hz, 1H,
Ar-H), 6.94 (td, J = 1.1 Hz, J = 7.6 Hz, 1H, Ar-H), 7.12 (td, J = 1.1 Hz, J = 7.6 Hz, 1H,
Ar-H); 7.61 (d, J = 9.2 Hz, 1H, Ar-H), 7.63 (s, 1H, vinyl-H), 8.45 (d, J = 9.1 Hz, 2H, ArH), 10.47 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 109.32, 111.50, 118.82,
120.77, 121.00, 122.54, 126.57, 127.41, 135.15, 138.39, 139.95, 152.18, 168.09; 13CNMR DEPT 135 (DMSO-d6, 300 MHz) δ: 40.06, 109.32, 111.49, 118.84, 121.00,
127.41, 135.16, 138.41 ppm.

{3-[p-(Dimethylamino)phenyl]-2-propenylidene}-indolin-2-one <TK-8-81 T> (83)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.4276 g, 3.211 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-(dimethylamino)cinnamaldehyde (0.6749 g, 3.853 mmol,
1.200 equiv.) was added and stirred at 90 °C for 19 min. Piperidine (0.0466 mL, 0.472

105

mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 2 h while stirring. The vial was cooled to rt. A red precipitate (0.1500 g, 16.1 %)
was collected by vacuum filtration. The sample was then triturated with EtOH to yield
the pure product (0.073 g) as a red solid: mp 214-215 °C (no lit. mp); Rf 0.47, 0.57 (50:50
EtOAc/Hexane); GC/MS at 95.6 % pure (M+ 290.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.00 (s, 6H, dimethylamino-H), 6.79 (m, 3H, Ar-H), 7.24 (m, 5H, Ar-H), 7.77 (m, 3H,
Ar-H), 10.38 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 40.18, 109.88, 112.35,
118.77, 121.62, 122.84, 123.19, 123.85, 124.03, 128.49, 130.25, 136.58, 141.92, 146.42,
151.79, 169.56 ppm.

3-(6-methoxy-2-naphthylbenzylidene)-indolin-2-one <TK-8-37 T> (84)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8547 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 6-methoxy-2-naphthaldehyde (1.4350 g, 7.706 mmol, 1.200
equiv.) was added and stirred at 90 °C for 21 min. Piperidine (0.0934 mL, 0.944 mmol,
0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for
3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow-orange precipitate (1.3107 g, 67.7 %) was collected by vacuum
filtration. The sample was then triturated with EtOH to yield the pure product (0.2852 g)
as a yellow-orange solid: mp 240-247 °C (no lit. mp); Rf 0.51 (30:70 EtOAc/Hexane);
GC/MS at 97.4 % pure (M+ 301.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 3.91 (s, 3H, OCH3), 6.84 (d, J = 7.3 Hz, 1H, Ar-H), 7.01 (td, J = 1.0 Hz, J = 7.6 Hz, 1H, Ar-H), 7.22
(m, 2H, Ar-H), 7.37 (d, J = 2.5 Hz, 1H, Ar-H), 7.74 (d, J = 7.3 Hz, 1H, Ar-H), 7.88 (m,
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3H, Ar-H), 8.64 (dd, J = 1.7 Hz, J = 8.8 Hz, 1H, Ar-H), 8.79 (d, J = 0.9 Hz, 1H, Ar-H),
10.65 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 55.82, 106.51, 109.76, 119.57,
120.02, 121.48, 125.66, 126.30, 126.78, 128.34, 129.13, 129.64, 130.12, 130.96, 133.25,
135.76, 137.50, 141.05, 159.24, 167.70 ppm.

3-(4-toluenebenzylidene)-indolin-2-one <TK-8-101 R> (85)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8546 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-tolualdehyde (0.9100 mL, 7.706 mmol, 1.200 equiv.) was
added and stirred at 90 °C for 6 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147 equiv.)
was then added dropwise and the vial was placed on a hot plate at 90 °C for 19 min while
stirring. The vial was cooled to rt and placed into an ice bath to induce crystallization. A
bright yellow precipitate (1.1929 g, 78.9 %) was collected by vacuum filtration. The
sample was then recrystallized with EtOH to yield the pure product (0.2570 g) as yellow
crystals: mp 186-201 °C (lit. mp128 199-200 °C); Rf 0.72 (50:50 EtOAc/Hexane); GC/MS
at 100.0 % pure (M+ 235.2); 1H-NMR (DMSO-d6, 300 MHz) δ: 2.38 (s, 3H, methyl-H),
6.85 (td, J = 1.1 Hz, J = 7.6 Hz, 1H, Ar-H), 6.87 (apparent d, J = 7.3 Hz, 1H, Ar-H), 7.22
(td, J = 1.2 Hz, J = 7.6 Hz, 1H, Ar-H), 7.33 (d, J = 8.0 Hz, 2H, Ar-H), 7.60 (m, 4H, ArH), 10.59 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 21.55, 110.54, 121.46,
121.52, 122.71, 127.38, 129.79, 129.86, 130.41, 131.99, 136.42, 140.13, 143.29, 169.18
ppm.

3-(4-bromobenzylidene)-indolin-2-one <TK-11-63 R> (86)
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To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8547 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-bromobenzaldehyde (1.4256 g, 7.706 mmol, 1.200 equiv.)
was added and stirred at 90 °C for 13 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147
equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for 17
min while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A light orange precipitate (1.5229 g, 79.0 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.2746 g) as yellow-orange solid: mp 187-188 °C (lit. mp132 191-192 °C); Rf 0.47 (30:70
EtOAc/Hexane); GC/MS at 99.3 % pure (M+ 299.0); 1H-NMR (DMSO-d6, 300 MHz) δ:
6.85 (td, J = 1.1 Hz, J = 7.6 Hz, 1H, Ar-H), 6.88 (d, J = 7.7 Hz, 1H, Ar-H), 7.24 (td, J =
1.1 Hz, J = 7.7 Hz, 1H, Ar-H), 7.48 (d, J = 7.7 Hz, 1H, Ar-H), 7.56 (s, 1H, vinyl-H), 7.65
(d, J = 8.4 Hz, 2H, Ar-H), 7.72 (d, J = 8.5 Hz, 2H, Ar-H), 10.64 (s, 1H, N-H); 13C-NMR
(DMSO-d6, 300 MHz) δ: 110.68, 121.11, 121.69, 122.95, 123.33, 128.66, 130.84,
131.76, 132.23, 134.16, 134.78, 143.53, 168.91 ppm.

3-(4-chlorobenzylidene)-indolin-2-one <TK-13-61 R> (87)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8555 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, 4-chlorobenzaldehyde (0.9027 g, 6.422 mmol, 1.000 equiv.)
was added and stirred at 90 °C for 22 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147
equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for 20
min while stirring. The vial was cooled to rt and placed into an ice bath to induce
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crystallization. A bright yellow-orange precipitate (1.1135 g, 67.8 %) was collected by
vacuum filtration. The sample was then recrystallized with EtOH to yield the pure
product (0.2324 g) as a fluffy orange solid: mp 185-189 °C (lit. mp128 189-191 °C); Rf
0.48 (30:70 EtOAc/Hexane); GC/MS at 99.4 % pure (M+ 255.1); 1H-NMR (DMSO-d6,
300 MHz) δ: 6.85 (td, J = 6.9 Hz, 1H, Ar-H), 6.88 (d, J = 7.8 Hz, 1H, Ar-H), 7.23 (td, J =
1.1 Hz, J = 7.7 Hz, 1H, Ar-H), 7.48 (d, J = 7.6 Hz, 1H, Ar-H), 7.57 (d, J = 8.6 Hz, 2H,
Ar-H), 7.59 (s, 1H, vinyl-H), 7.72 (d, J = 8.3 Hz, 2H, Ar-H), 10.64 (s, 1H, N-H); 13CNMR (DMSO-d6, 300 MHz) δ: 110.67, 121.11, 121.67, 122.92, 128.67, 129.29, 130.82,
131.54, 133.80, 134.57, 134.72, 143.53, 168.92 ppm.

3-(benzylidene)-indolin-2-one <TK-7-127> (88)
To a 2 Dram vial charged with EtOH (4 mL), indolin-2-one (0.8554 g, 6.422 mmol) and a
stir bar were added. The vial was capped and placed to stir at 90 °C until full dissolution.
Following full dissolution, benzaldehyde (0.9500 mL, 7.706 mmol, 1.200 equiv.) was
added and stirred at 90 °C for 10 min. Piperidine (0.0934 mL, 0.944 mmol, 0.147 equiv.)
was then added dropwise and the vial was placed on a hot plate at 90 °C for 3 h while
stirring. The vial was cooled to rt and placed into an ice bath to induce crystallization. A
dark-yellow precipitate (0.7043 g, 49.5 %) was collected by vacuum filtration: mp 166167 °C (lit. mp128 179-180 °C); Rf 0.62 (50:50 EtOAc/Hexane); GCMS at 100.0 % pure
(M+ 221.1); 1H-NMR (Acetone-d6, 300 MHz) δ: 6.86 (td, J = 1.0 Hz, J = 7.7 Hz, 1H, ArH), 6.97 (d, J = 7.7 Hz, 1H, Ar-H), 7.25 (td, J = 1.1 Hz, J = 7.7 Hz, 1H, Ar-H), 7.54 (m,
3H, Ar-H), 7.63 (d, J = 7.7 Hz, 1H, Ar-H), 7.71 (s, 1H, vinyl-H), 7.74 (apparent d, J =
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8.1 Hz, 2H, Ar-H), 9.62 (s, 1H, N-H); 13C-NMR (Acetone-d6, 300 MHz) δ: 169.5, 144.0,
136.6, 135.9, 131.0, 130.4, 130.1, 129.6, 128.9, 123.6, 122.3, 122.0, 110.9 ppm.

6.3. 5-Fluoroindolin-2-one Derivatives

5-fluoro-3-(4-methoxybenzylidene)-indolin-2-one <TK-8-169> (89)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9705 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, p-anisaldehyde (0.9400 mL, 7.706 mmol, 1.200
equiv.) was added and stirred at 90 °C for 16 min. Piperidine (0.0934 mL, 0.944 mmol,
0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for
1 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A reddish brown precipitate (1.4863 g, 85.9 %) was collected by vacuum
filtration: mp 200-202 °C (no lit. mp); Rf 0.46 (30:70 EtOAc/Hexane); GC/MS at 100.0
% pure (M+ 269.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 3.84 (s, 3H, -OCH3), 6.79 (dd,
3J

H-F

= 4.4 Hz, JH-H = 8.5 Hz, 1H, Ar-H), 7.04 (m, 4H, Ar-H), 7.59 (dd, JH-H = 2.6 Hz,

2

JH-F = 9.1 Hz, Ar-H), 7.68 (m, 1H, Ar-H), 7.81 (s, 1H, vinyl-H), 8.49 (d, J = 7.1 Hz, 2H,

Ar-H), 10.59 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 55.83, 107.11 (d, 2JC-F =
25.4 Hz), 110.31 (d, 3JC-F = 8.3 Hz), 114.27, 114.72 (d, 2JC-F = 24.1 Hz), 114.81, 124.10
(d, 4JC-F = 2.9 Hz), 127.22, 127.38 (d, 3JC-F = 8.9 Hz), 132.05, 135.16, 136.85 (d, 4JC-F =
1.4 Hz), 138.99, 158.38 (d, 1JC-F = 234.7 Hz), 161.94, 167.88 ppm.

5-fluoro-3-(2-methoxybenzylidene)-indolin-2-one <TK-8-1 T> (90)
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To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9709 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 2-methoxybenzaldehyde (1.0490 g, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 17 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A yellow-gray precipitate (1.5965 g, 92.3 %) was collected by vacuum
filtration. The sample was then triturated with EtOH to yield the pure product (0.3081 g)
as a yellow solid: mp 225-226 °C (no lit. mp); Rf 0.53 (50:50 EtOAc/Hexane); GC/MS at
100.0 % pure (M+ 269.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 3.86 (s, 3H, -OCH3), 6.85
(ddd, JH-H = 0.9 Hz, 3JH-F = 4.7 Hz, JH-H = 7.9 Hz, 1H, Ar-H), 7.07 (m, 3H, Ar-H), 7.18
(d, J = 8.1 Hz, 1H, Ar-H), 7.51 (apparent t, J = 7.9 Hz, 1H, Ar-H), 7.66 (dd, J = 1.1 Hz, J
= 7.5 Hz, 1H, Ar-H), 7.72 (s, 1H, vinyl-H), 10.62 (s, 1H, N-H); 13C-NMR (DMSO-d6,
300 MHz) δ: 56.09, 109.71 (d, 2JC-F = 25.8 Hz), 111.15 (d, 3JC-F = 8.3 Hz), 112.19,
116.59 (d, 2JC-F = 23.7 Hz), 120.76, 122.56 (d, 3JC-F = 9.0 Hz), 122.86, 127.58 (d, 4JC-F =
2.8 Hz), 129.93, 129.93, 132.57, 133.88, 139.52 (d, 4JC-F = 1.5 Hz), 157.60 (d, 1JC-F =
235.2 Hz), 158.11, 168.99 ppm.

5-fluoro-3-(2,5-dimethoxybenzylidene)-indolin-2-one <TK-8-113 R> (91)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9708 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 2,5-dimethoxybenzaldehyde (1.2802 g, 7.706
mmol, 1.200 equiv.) was added and stirred at 90 °C for 3 min. Piperidine (0.0934 mL,
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0.944 mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot
plate at 90 °C for 1 h while stirring. The vial was cooled to rt and placed into an ice bath
to induce crystallization. A yellow precipitate (1.8274 g, 95.1 %) was collected by
vacuum filtration: mp 209-214 °C (no lit. mp); Rf 0.63, 0.71 (50:50 EtOAc/Hexane);
GC/MS at 99.8 % pure (M+ 299.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 3.73 (s, 3H, OCH3), 3.80 (s, 3H, -OCH3), 6.85 (dd, 3JH-F = 4.6 Hz, JH-H = 8.5 Hz, 1H, Ar-H), 7.09 (m,
4H, Ar-H), 7.20 (apparent d, J = 1.6 Hz, 1H, Ar-H), 7.68 (s, 1H, vinyl-H), 10.63 (s, 1H,
N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 56.06, 56.41, 109.87 (d, 2JC-F = 25.8 Hz),
111.19 (d, 3JC-F = 8.4 Hz), 113.30, 114.86, 116.64 (d, 2JC-F = 23.7 Hz), 117.72, 122.53 (d,
3

JH-F = 8.9 Hz), 123.38, 127.80 (d, 2JC-F = 2.8 Hz), 133.49, 139.60 (d, 4JC-F = 1.5 Hz),

152.31, 153.09, 157.60 (d, 1JC-F = 235.3 Hz), 168.99 ppm.

5-fluoro-3-(3,4,5-trimethoxybenzylidene)-indolin-2-one <TK-12-187 T> (92)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9705 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 3,4,5-trimethoxybenzaldehyde (1.5119 g, 7.706
mmol, 1.200 equiv.) was added and stirred at 90 °C for 6 min. Piperidine (0.0934 mL,
0.944 mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot
plate at 90 °C for 2 h while stirring. The vial was cooled to rt and placed into an ice bath
to induce crystallization. A yellow precipitate (1.8084 g, 85.5 %) was collected by
vacuum filtration: mp 243-248 °C (lit. mp135 194-196 °C); Rf 0.71 (50:50
EtOAc/Hexane); GC-MS at 97.3 % pure (M+ 329.2); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.76 (s, 3H, -OCH3), 3.85 (s, 6H, -OCH3), 6.82 (dd, 3JH-F = 4.4 Hz, J = 8.5 Hz, 1H, Ar-
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H), 7.03 (ddd, JH-H = 2.6 Hz, JH-H = 8.5 Hz, 2JH-F = 9.6 Hz, 1H, Ar-H), 7.60 (dd, JH-H =
2.6 Hz, 2JH-F = 9.1 Hz, 1H, Ar-H), 7.84 (s, 1H, vinyl-H), 8.03 (s, 2H, Ar-H), 10.60 (s, 1H,
N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 56.35, 60.64, 107.27 (d, 2JC-F = 25.4 Hz),
110.52 (d, 3JC-F = 8.3 Hz), 110.87, 115.18 (d, 2JC-F = 23.9 Hz), 124.67 (d, 4JC-F = 3.0 Hz),
127.21 (d, 3JC-F = 9.0 Hz), 129.74, 137.10 (d, 4JC-F = 1.3 Hz), 139.48, 140.62, 152.72,
158.41 (d, 1JC-F = 234.7 Hz), 167.78 ppm.

5-fluoro-3-(2,4,6-trimethoxybenzylidene)-indolin-2-one <TK-7-183 R> (93)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9708 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 2,4,6-trimethoxybenzaldehyde (1.5118 g, 7.706
mmol, 1.200 equiv.) was added and stirred at 90 °C for 23 min. Piperidine (0.0934 mL,
0.944 mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot
plate at 90 °C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath
to induce crystallization. A yellow precipitate (1.7320 g, 81.9 %) was collected by
vacuum filtration. The sample was then recrystallized with EtOH to afford the pure
product (0.2560 g) as a yellow solid: mp 215-217 °C (no lit. mp); Rf 0.52, 0.63 (50:50
EtOAc/Hexane); GC/MS at 100.0 % pure (M+ 329.2); 1H-NMR (DMSO-d6, 300 MHz) δ:
3.78 (s, 6H, -OCH3), 3.88 (s, 3H, -OCH3), 6.38 (s, 2H, Ar-H), 6.52 (dd, JH-H = 2.6 Hz,
2J

H-F

= 9.5 Hz, 1H, Ar-H), 6.89 (dd, 3JH-F = 4.6 Hz, JH-H = 8.5 Hz, 1H, Ar-H), 7.01 (ddd,

JH-H = 2.7 Hz, JH-H = 8.5 Hz, 2JH-F = 9.5 Hz, 1H, Ar-H), 7.49 (s, 1H, Ar-H), 10.48 (s, 1H,
N-H); 13C-NMR (CDCl3, 300 MHz) δ: 56.03, 56.16, 91.34, 104.80, 110.21 (d, 3JC-F = 8.3
Hz), 111.08 (d, 2JC-F = 25.6 Hz), 115.26 (d, 2JC-F = 23.6 Hz), 124.09 (d, 3JC-F = 9.3 Hz),
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127.30 (d, 4JC-F = 2.8 Hz), 129.10, 138.65 (d, 4JC-F = 1.3 Hz), 157.92 (d, 1JC-F = 233.9
Hz), 159.59, 163.66, 169.45 ppm.

5-fluoro-3-(3-hydroxy-4-methoxybenzylidene)-indolin-2-one <TK-7-139> (94)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9706 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 3-hydroxy-4-methoxybenzaldehyde (1.1723 g,
7.706 mmol, 1.200 equiv.) was added and stirred at 90 °C for 14 min. Piperidine (0.0934
mL, 0.944 mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot
plate at 90 °C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath
to induce crystallization. A golden brown precipitate (1.0665 g, 68.6 %) was collected by
vacuum filtration: mp 238-242 °C (no lit. mp); Rf 0.47 (50:50 EtOAc/Hexane); GC/MS at
99.9 % pure (M+ 285.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 3.86 (s, 3H, -OCH3), 6.86
(dd, 3JH-F = 4.7 Hz, JH-H = 8.5 Hz, 1H, Ar-H), 7.07 (m, 2H, Ar-H), 7.18 (m, 2H, Ar-H),
7.46 (dd, JH-H = 2.5 Hz, 2JH-F = 9.5 Hz, 1H, Ar-H), 7.57 (s, 1H, vinyl-H), 9.50 (s, 1H, OH), 10.58 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 56.11, 109.80 (d, 2JC-F = 26.1
Hz), 111.02 (d, 3JC-F = 8.5 Hz), 112.63, 116.22 (d, 2JC-F = 23.7 Hz), 116.55, 122.62 (d,
3J

C-F

= 9.0 Hz), 122.86, 125.43 (d, 4JC-F = 2.8 Hz), 126.91, 138.59, 139.37 (d, 4JC-F = 1.2

Hz), 147.01, 150.22, 157.63 (d, 1JC-F = 234.6 Hz), 169.43 ppm.

5-fluoro-3-(4-hydroxybenzylidene)-indolin-2-one <TK-8-93 R> (95)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9708 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
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dissolution. Following full dissolution, 4-hydroxybenzaldehyde (0.9412 g, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 19 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 7 min while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A bright yellow precipitate (1.5165 g, 92.5 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.1935 g) as a yellow solid: mp > 250 °C (no lit. mp); Rf 0.41 (50:50 EtOAc/Hexane).
GC/MS at 93.2 % pure (M+ 255.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 6.85 (dd, 3JH-F =
4.7 Hz, JH-H = 8.6 Hz, 1H, Ar-H), 6.93 (d, J = 8.7 Hz, 2H, Ar-H), 7.05 (ddd, JH-H = 2.6
Hz, J = 8.6 Hz, 2JH-F = 9.2 Hz, 1H, Ar-H), 7.39 (dd, JH-H = 2.5 Hz, 2JH-F = 9.5 Hz, 1H, ArH), 7.61 (d, J = 8.4 Hz, 2H, Ar-H), 7.61 (s, 1H, vinyl-H), 10.23 (s, 1H, O-H), 10.56 (s,
1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 109.44 (d, 2JC-F = 25.9 Hz), 110.96 (d, 3JCF

= 8.4 Hz), 116.03 (d, 2JC-F = 23.7 Hz), 116.23, 122.75 (d, 3JC-F = 9.0 Hz), 124.83 (d, 4JC-

F

= 2.9 Hz), 125.08, 132.40, 139.24 (d, 4JC-F = 1.3 Hz), 157.61 (d, 1JC-F = 234.6 Hz),

160.11, 169.48 ppm.

5-fluoro-3-(2-hydroxybenzylidene)-indolin-2-one <TK-8-97 R> (96)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9705 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, salicylaldehyde (0.820 mL, 7.706 mmol, 1.200
equiv.) was added and stirred at 90 °C for 6 min. Piperidine (0.0934 mL, 0.944 mmol,
0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for
5 min while stirring. The vial was cooled to rt and placed into an ice bath to induce
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crystallization. A bright yellow precipitate (1.5787 g, 96.3 %) was collected by vacuum
filtration. The sample was then recrystallized with EtOH to yield the pure product
(0.2576 g) as a light orange solid: mp 197-200 °C (no lit. mp); Rf 0.52 (50:50
EtOAc/Hexane); GC/MS at 47.8 % pure (M+ 255.1); 1H-NMR (DMSO-d6, 300 MHz) δ:
6.85 (dd, 3JH-F = 4.7 Hz, JH-H = 8.5 Hz, 1H, Ar-H), 6.97 (m, 2H, Ar-H), 7.06 (td, J = 2.6
Hz, J = 9.1 Hz, 1H, Ar-H), 7.18 (dd, JH-H = 2.5 Hz, 2JH-F = 9.4 Hz, 1H, Ar-H), 7.34
(apparent td, J = 1.5 Hz, J = 7.6 Hz, 1H, Ar-H), 7.60 (dd, J = 1.0 Hz, J = 7.6 Hz, 1H, ArH), 7.76 (s, 1H, vinyl-H), 10.27 (s, 1H, O-H), 10.60 (s, 1H, N-H); 13C-NMR (DMSO-d6,
300 MHz) δ: 109.85 (d, 2JC-F = 25.7 Hz), 111.00 (d, 3JC-F = 8.4 Hz), 116.31 (d, 2JC-F =
23.7 Hz), 116.58, 119.38, 121.38, 122.78 (d, 2JC-F = 9.0 Hz), 126.77 (d, 4JC-F = 2.9 Hz),
130.01, 132.42, 134.57, 139.36 (d, 4JC-F = 1.5 Hz), 156.97, 157.60 (d, 1JC-F = 234.6 Hz),
169.21 ppm.

5-fluoro-3-(2-fluorobenzylidene)-indolin-2-one <TK-7-191 T> (97)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9704 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 2-fluorobenzaldehyde (0.8120 mL, 7.706 mmol,
1.200 equiv.) was added and stirred at 90 °C for 12 min. Piperidine (0.0934 mL, 0.944
mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90
°C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. A bright yellow precipitate (1.4091 g, 85.3 %) was collected by vacuum
filtration: mp 132-135 °C (no lit. mp); Rf 0.76 (50:50 EtOAc/Hexane); GC/MS at 100.0
% pure (M+ 257.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 6.87 (dd, 3JH-F = 4.5 Hz, JH-H =
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8.6 Hz, 1H, Ar-H), 6.93 (apparent d, J = 9.1 Hz, 1H, Ar-H), 7.11 (ddd, JH-H = 2.6 Hz, JHH

= 8.6 Hz, 2JH-F = 9.4 Hz, 1H, Ar-H), 7.40 (m, 2H, Ar-H), 7.58 (m, 1H, Ar-H), 7.62 (s,

1H, vinyl-H), 7.76 (apparent t, J = 7.0 Hz, 1H, Ar-H), 10.71 (s, 1H, N-H); 13C-NMR
(DMSO-d6, 300 MHz) δ: 109.95 (d, 4JC-F = 1.7 Hz), 110.29 (d, 4JC-F = 1.7 Hz), 111.41 (d,
3J

C-F

= 8.2 Hz), 116.62 (d, 2JC-F = 21.1 Hz), 117.33 (d, 2JC-F = 23.6 Hz), 122.11 (d, 2JC-F =

18.6 Hz), 122.33 (d, 2JC-F = 24.2 Hz), 125.31 (d, 3JC-F = 3.4 Hz), 129.60 (4JC-F = 1.7 Hz),
130.00 (d, 4JC-F = 2.3 Hz), 132.80 (d, 3JC-F = 8.5 Hz), 139.94 (d, 4JC-F = 1.4 Hz), 151.50,
157.69 (d, 1JC-F = 235.5 Hz), 160.06 (d, 1JC-F = 249.0 Hz), 168.48 ppm.

3-(4-Nitrobenzylidene)-5-fluoroindolin-2-one <MVP-1-45 T> (98)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9705 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 4-nitrobenzaldehyde (1.164 g, 7.706 mmol, 1.200
equiv.) was added and stirred at 90 °C for 15 min. Piperidine (0.0934 mL, 0.944 mmol,
0.147 equiv.) was then added dropwise and the vial was placed on a hot plate at 90 °C for
3 h while stirring. The vial was cooled to rt and placed into an ice bath to induce
crystallization. An orange precipitate (1.6430 g, 90.0 %) was collected by vacuum
filtration. The sample was then purified with silica gel (30:70 EtOAc/Hexane) to yield the
pure product as a red-orange solid: mp 261-266 °C (no lit. mp); Rf 0.30 (30:70
EtOAc/Hexane); GC-MS at 100.0 % pure (M+ 266.1); 1H-NMR (DMSO-d6, 300 MHz) δ
[E-isomer]: 8.33 (d, J = 8.8 Hz, 2H, Ar-H), 7.92 (d, J = 8.3 Hz, 2H, Ar-H), 7.71 (s, 1H,
vinyl-H), 7.08 (m, 2H, Ar-H), 6.83 (m, 1H, Ar-H), 10.71 (s, N-H); [Z-isomer]: 8.47 (d, J
= 8.9 Hz, 2H, Ar-H), 8.26 (d, J = 8.9 Hz, 2H, Ar-H), 7.93 (s, 1H, vinyl-H), 7.62 (dd, J =
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8.9, 1H, Ar-H) 7.08 (m, 1H, Ar-H), 6.83 (m, 1H, Ar-H), 10.71 (s, N-H); 13C-NMR
(DMSO-d6, 300 MHz) δ [E-isomer]: 108.48 (d, 2JC-F = 25.4 Hz), 110.93 (d, 3JC-F = 8.1
Hz), 116.79 (d, 2JC-F = 24.0 Hz), 121.59 (d, 3JC-F = 8.8 Hz), 123.58, 130.16 (d, 4JC-F = 3.1
Hz), 130.86, 135.02, 138.19 (d, 4JC-F = 1.5 Hz), 140.30, 148.01, 157.63 (d, 1JC-F = 235.9
Hz), 167.19 ppm; [Z-isomer]: 110.35 (d, 2JC-F = 25.6 Hz), 111.58 (d, 3JC-F = 8.3 Hz),
117.77 (d, 2JC-F = 23.7 Hz), 124.44, 126.05 (d, 3JC-F = 9.0 Hz), 130.22 (d, 4JC-F = 3.3 Hz),
133.05, 135.53, 140.25 (d, 4JC-F = 1.4 Hz), 141.30, 148.09, 158.42 (d, 1JC-F = 235.6 Hz),
168.57 ppm.

5-fluoro-3-(4-dimethylaminobenzylidene)-indolin-2-one <TK-7-67 T> (99)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.9708 g, 6.422
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 4-(dimethylamino)benzaldehyde (1.1498 g, 7.706
mmol, 1.200 equiv.) was added and stirred at 90 °C for 5 min. Piperidine (0.0934 mL,
0.944 mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot
plate at 90 °C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath
to induce crystallization. A light orange precipitate (1.6569 g, 91.4 %) was collected by
vacuum filtration: mp 258-260 °C (no lit. mp); Rf 0.49, 0.62 (50:50 EtOAc/Hexane);
GC/MS at 100.0 % pure (M+ 282.1); 1H-NMR (DMSO-d6, 300 MHz) δ: 3.04 (s, 6H,
dimethylamino-H), 6.84 (m, 3H, Ar-H), 7.03 (ddd, JH-H = 2.6 Hz, JH-H = 8.6 Hz, 2JH-F =
9.4 Hz, 1H, Ar-H), 7.50 (dd, JH-H = 2.6 Hz, 2JH-F = 9.7 Hz, 1H, Ar-H), 7.59 (s, 1H, vinylH), 7.64 (d, J = 8.7 Hz, 2H, Ar-H), 10.48 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz)
δ: 40.09, 108.97 (d, 2JC-F = 25.9 Hz), 110.68 (d, 3JC-F = 8.4 Hz), 112.00, 115.16 (d, 2JC-F =
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23.6 Hz), 121.12, 122.13 (d, 4JC-F = 2.7 Hz), 123.31 (d, 3JC-F = 8.8 Hz), 132.56, 138.77,
139.43, 152.10, 157.65 (1JC-F = 234.1 Hz), 169.86 ppm.

5-fluoro-{3-[4-(dimethylamino)phenyl]-2-propenylidene}-indolin-2-one <TK-8-85
T> (100)
To a 2 Dram vial charged with EtOH (4 mL), 5-fluoroindolin-2-one (0.4853 g, 3.211
mmol) and a stir bar were added. The vial was capped and placed to stir at 90 °C until full
dissolution. Following full dissolution, 4-(dimethylamino)cinnamaldehyde (0.6750 g,
3.853 mmol, 1.200 equiv.) was added and stirred at 90 °C for 17 min. Piperidine (0.0472
mL, 0.472 mmol, 0.147 equiv.) was then added dropwise and the vial was placed on a hot
plate at 90 °C for 2 h while stirring. The vial was cooled to rt. A red precipitate (0.3117 g,
31.5 %) was collected by vacuum filtration. The sample was then triturated with EtOH to
yield the pure product (0.2792 g) as a red solid: mp 254-255 °C (no lit. mp); Rf 0.46, 0.53
(50:50 EtOAc/Hexane); GC/MS at 97.2 % pure (M+ 308.2); 1H-NMR (DMSO-d6, 300
MHz) δ: 3.00 (s, 6H, N-H), 6.90 (m, 4H, Ar-H), 7.38 (m, 3H, Ar-H), 7.77 (m, 3H, Ar-H),
10.38 (s, 1H, N-H); 13C-NMR (DMSO-d6, 300 MHz) δ: 40.15, 110.21 (d, 3JC-F = 8.5 Hz),
110.93 (d, 2JC-F = 25.6 Hz), 112.24, 114.48 (d, 2JC-F = 23.7 Hz), 118.52, 122.12 (d, 4JC-F =
2.2 Hz), 123.94, 124.08 (d, 3JC-F = 9.2 Hz), 130.75, 138.08, 138.30, 147.94, 151.94,
158.34 (d, 1JC-F = 234.3 Hz), 169.67 ppm.

6.4. 5-Chloroindolin-2-one Derivative
5-chloro-3-(4-methoxybenzylidene)-indolin-2-one <TK-7-109 R> (101)
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To a 2 Dram vial was added 5-chloroindolin-2-one (0.3240 g, 1.940 mmol) with panisaldehyde (0.2830 mL, 2.328 mmol, 1.200 equiv.), piperidine (0.0282 mL, 0.285
mmol, 0.147 equiv.), EtOH (4 mL), and a stir bar. The vial was placed on a hot plate at
90 °C for 3 h while stirring. The vial was cooled to rt and placed into an ice bath to
induce crystallization. A dark yellow precipitate (0.4131 g, 74.5 %) was collected by
vacuum filtration. The sample was then recrystallized with EtOH to yield the pure
product (0.0677 g) as a yellow solid: mp 168-170 °C (lit. mp135 257-260 °C); Rf 0.66,
0.78 (50:50 EtOAc/Hexane); GC/MS at 99.7 % pure (M+ 285.1); 1H-NMR (DMSO-d6,
300 MHz) δ: 3.86 (s, 3H, -OCH3), 6.89 (d, J = 8.3 Hz, 1H, Ar-H), 7.12 (d, J = 8.6 Hz,
2H, Ar-H), 7.28 (dd, J = 2.1 Hz, J = 8.3 Hz, 1H, Ar-H), 7.57 (d, J = 2.1 Hz, 1H, Ar-H),
7.67 (s, 1H, vinyl-H), 7.71 (d, J = 8.4 Hz, 2H, Ar-H), 10.71 (s, 1H, N-H); 13C-NMR
(DMSO-d6, 300 MHz) δ: 55.91, 111.82, 114.84, 121.88, 123.28, 125.19, 125.331,
126.64, 129.61, 132.08, 138.41, 141.86, 151.51, 161.36, 169.02 ppm.
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